

# INTELLECTUAL DISABILITY GENE PANEL DG 2.17 (1300 genes)

Releasedate: 06-12-2019

| <i>Gene</i> | <i>Median Coverage</i> | <i>% covered &gt; 10x</i> | <i>% covered &gt; 20x</i> | <i>Associated Phenotype description and OMIM disease ID</i>   |
|-------------|------------------------|---------------------------|---------------------------|---|
| AAAS        | 109.1                  | 100.0%                    | 99.8%                     | Achalasia-addisonianism-alacrimia syndrome, 231550  |
| AARS        | 109.2                  | 100.0%                    | 99.7%                     | Epileptic encephalopathy, early infantile, 29, 616339<br>Charcot-Marie-Tooth disease, axonal, type 2N, 613287   |
| AASS        | 131.3                  | 100.0%                    | 99.6%                     | Hyperlysinemia, 238700  |
| ABAT        | 86.1                   | 99.9%                     | 98.4%                     | GABA-transaminase deficiency, 613163  |
| ABCC8       | 134.7                  | 100.0%                    | 99.9%                     | Diabetes mellitus, permanent neonatal, 606176<br>Diabetes mellitus, noninsulin-dependent, 125853<br>Diabetes mellitus, transient neonatal 2, 610374<br>Hyperinsulinemic hypoglycemia, familial, 1, 256450<br>Hypoglycemia of infancy, leucine-sensitive, 240800 |
| ABCC9       | 140.4                  | 100.0%                    | 99.9%                     | Hypertrichotic osteochondrodysplasia, 239850<br>Atrial fibrillation, familial, 12, 614050<br>Cardiomyopathy, dilated, 10, 608569  |
| ABCD1       | 95.7                   | 77.7%                     | 74.9%                     | Adrenomyeloneuropathy, adult, 300100<br>Adrenoleukodystrophy, 300100  |
| ABCD4       | 139.9                  | 99.9%                     | 98.5%                     | Methylmalonic aciduria and homocystinuria, cblJ type, 614857  |
| ABHD5       | 183.6                  | 100.0%                    | 100.0%                    | Chanarin-Dorfman syndrome, 275630   |
| ACAD9       | 130.9                  | 100.0%                    | 98.8%                     | Mitochondrial complex I deficiency, nuclear type 20, 611126   |
| ACADS       | 164.6                  | 100.0%                    | 100.0%                    | Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470  |
| ACAT1       | 110.0                  | 99.9%                     | 97.1%                     | Alpha-methylacetoacetic aciduria, 203750  |
| ACO2        | 125.5                  | 95.6%                     | 90.3%                     | ?Optic atrophy 9, 616289<br>Infantile cerebellar-retinal degeneration, 614559   |
| ACOX1       | 129.5                  | 100.0%                    | 100.0%                    | Peroxisomal acyl-CoA oxidase deficiency, 264470   |
| ACSF3       | 158.9                  | 99.9%                     | 99.4%                     | Combined malonic and methylmalonic aciduria, 614265   |
| ACSL4       | 100.3                  | 98.2%                     | 92.7%                     | Mental retardation, X-linked 63, 300387   |
| ACTB        | 92.6                   | 100.0%                    | 99.9%                     | ?Dystonia, juvenile-onset, 607371<br>Baraitser-Winter syndrome 1, 243310  |
| ACTG1       | 131.2                  | 100.0%                    | 100.0%                    | Baraitser-Winter syndrome 2, 614583<br>Deafness, autosomal dominant 20/26, 604717   |
| ACTL6A      | 124.1                  | 99.9%                     | 98.6%                     | No OMIM Disease ID  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| ACTL6B   | 144.9 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 76, 618468<br>Intellectual developmental disorder with severe speech and ambulation defects, 618470  |
| ACVR1    | 139.8 | 100.0% | 100.0% | Fibrodysplasia ossificans progressiva, 135100   |
| ACY1     | 128.5 | 99.9%  | 99.1%  | Aminoacylase 1 deficiency, 609924   |
| ADAM22   | 133.4 | 100.0% | 99.4%  | ?Epileptic encephalopathy, early infantile, 61, 617933  |
| ADAR     | 117.2 | 99.9%  | 99.4%  | Aicardi-Goutieres syndrome 6, 615010<br>Dyschromatosis symmetrica hereditaria, 127400   |
| ADAT3    | 153.0 | 100.0% | 100.0% | Mental retardation, autosomal recessive 36, 615286  |
| ADGRG1   | 159.1 | 100.0% | 100.0% | Polymicrogyria, bilateral perisylvian, 615752<br>Polymicrogyria, bilateral frontoparietal, 606854   |
| ADK      | 101.3 | 99.9%  | 97.3%  | Hypermethioninemia due to adenosine kinase deficiency, 614300   |
| ADNP     | 198.1 | 100.0% | 100.0% | Helsmoortel-van der Aa syndrome, 615873   |
| ADPRHL2  | 177.4 | 100.0% | 100.0% | Neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures, 618170   |
| ADSL     | 147.2 | 99.2%  | 98.9%  | Adenylosuccinase deficiency, 103050   |
| AFF2     | 109.6 | 99.9%  | 98.8%  | Mental retardation, X-linked, FRAXE type, 309548  |
| AFF4     | 102.7 | 99.9%  | 98.7%  | CHOPS syndrome, 616368  |
| AFG3L2   | 100.8 | 95.7%  | 85.1%  | Spastic ataxia 5, autosomal recessive, 614487<br>Spinocerebellar ataxia 28, 610246  |
| AGA      | 144.3 | 100.0% | 100.0% | Aspartylglucosaminuria, 208400  |
| AGO2     | 128.6 | 99.2%  | 99.1%  | No OMIM Disease ID  |
| AHCY     | 120.8 | 100.0% | 98.5%  | Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752  |
| AHDC1    | 172.9 | 99.9%  | 98.8%  | Xia-Gibbs syndrome, 615829  |
| AHI1     | 125.5 | 99.9%  | 97.6%  | Joubert syndrome 3, 608629  |
| AHSG     | 173.3 | 100.0% | 99.9%  | ?Alopecia-mental retardation syndrome 1, 203650   |
| AIFM1    | 92.9  | 99.7%  | 96.5%  | Cowchock syndrome, 310490<br>Spondyloepimetaphyseal dysplasia, X-linked, with hypomyelinating leukodystrophy, 300232<br>Combined oxidative phosphorylation deficiency 6, 300816<br>Deafness, X-linked 5, 300614 |
| AIMP1    | 80.4  | 99.1%  | 91.4%  | Leukodystrophy, hypomyelinating, 3, 260600  |
| AIMP2    | 126.1 | 97.0%  | 89.6%  | Leukodystrophy, hypomyelinating, 17, 618006   |
| AKT3     | 79.2  | 98.6%  | 94.0%  | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937  |
| ALDH18A1 | 116.9 | 100.0% | 99.8%  | Cutis laxa, autosomal recessive, type IIIA, 219150<br>Cutis laxa, autosomal dominant 3, 616603<br>Spastic paraplegia 9B, autosomal recessive, 616586<br>Spastic paraplegia 9A, autosomal dominant, 601162       |
| ALDH3A2  | 116.9 | 95.3%  | 94.2%  | Sjogren-Larsson syndrome, 270200  |
| ALDH4A1  | 136.8 | 100.0% | 99.8%  | Hyperprolinemia, type II, 239510  |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| ALDH5A1 | 95.5  | 99.6%  | 95.6%  | Succinic semialdehyde dehydrogenase deficiency, 271980   |
| ALDH7A1 | 68.0  | 94.2%  | 86.7%  | Epilepsy, pyridoxine-dependent, 266100   |
| ALG1    | 51.3  | 53.6%  | 52.1%  | Congenital disorder of glycosylation, type Ik, 608540  |
| ALG11   | 132.1 | 96.8%  | 96.5%  | Congenital disorder of glycosylation, type Ip, 613661  |
| ALG12   | 169.5 | 100.0% | 100.0% | Congenital disorder of glycosylation, type Ig, 607143  |
| ALG13   | 77.7  | 98.6%  | 92.4%  | Epileptic encephalopathy, early infantile, 36, 300884<br>?Congenital disorder of glycosylation, type Is, 300884                |
| ALG2    | 112.6 | 100.0% | 100.0% | Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228<br>?Congenital disorder of glycosylation, type Ii, 607906 |
| ALG3    | 117.9 | 100.0% | 100.0% | Congenital disorder of glycosylation, type Id, 601110  |
| ALG6    | 98.1  | 98.9%  | 94.9%  | Congenital disorder of glycosylation, type Ic, 603147  |
| ALG8    | 118.5 | 96.8%  | 95.7%  | Congenital disorder of glycosylation, type Ih, 608104<br>Polycystic liver disease 3 with or without kidney cysts, 617874       |
| ALG9    | 114.8 | 100.0% | 99.8%  | Gillessen-Kaesbach-Nishimura syndrome, 263210<br>Congenital disorder of glycosylation, type IJ, 608776                         |
| ALMS1   | 178.0 | 100.0% | 99.8%  | Alstrom syndrome, 203800   |
| ALX3    | 148.9 | 91.7%  | 80.3%  | Frontonasal dysplasia 1, 136760  |
| ALX4    | 175.4 | 100.0% | 100.0% | Frontonasal dysplasia 2, 613451<br>Parietal foramina 2, 609597   |
| AMER1   | 106.2 | 99.8%  | 99.1%  | Osteopathia striata with cranial sclerosis, 300373   |
| AMMECR1 | 102.3 | 100.0% | 99.6%  | Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis, 300990   |
| AMPD2   | 146.3 | 100.0% | 100.0% | ?Spastic paraplegia 63, 615686<br>Pontocerebellar hypoplasia, type 9, 615809   |
| AMT     | 151.3 | 100.0% | 100.0% | Glycine encephalopathy, 605899   |
| ANK3    | 144.2 | 99.4%  | 99.2%  | ?Mental retardation, autosomal recessive, 37, 615493   |
| ANKH    | 116.6 | 100.0% | 100.0% | Chondrocalcinosis 2, 118600<br>Craniometaphyseal dysplasia, 123000   |
| ANKLE2  | 155.0 | 100.0% | 99.9%  | Microcephaly 16, primary, autosomal recessive, 616681  |
| ANKRD11 | 131.8 | 99.6%  | 97.6%  | KBG syndrome, 148050   |
| ANKS1B  | 122.4 | 100.0% | 99.5%  | No OMIM Disease ID   |
| ANO10   | 106.0 | 98.6%  | 96.5%  | Spinocerebellar ataxia, autosomal recessive 10, 613728   |
| ANTXR1  | 112.9 | 99.3%  | 97.3%  | GAPO syndrome, 230740  |
| AP1S1   | 105.8 | 100.0% | 99.9%  | MEDNIK syndrome, 609313  |
| AP1S2   | 50.8  | 75.6%  | 68.1%  | Mental retardation, X-linked syndromic 5, 304340   |
| AP2M1   | 115.2 | 100.0% | 99.9%  | Intellectual developmental disorder 60 with seizures, 618587   |
| AP3B1   | 108.2 | 99.4%  | 95.7%  | Hermansky-Pudlak syndrome 2, 608233  |
| AP3B2   | 135.0 | 99.8%  | 97.9%  | Epileptic encephalopathy, early infantile, 48, 617276  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| AP3D1    | 135.1 | 98.5%  | 97.9%  | ?Hermansky-Pudlak syndrome 10, 617050   |
| AP4B1    | 124.8 | 99.9%  | 98.7%  | Spastic paraplegia 47, autosomal recessive, 614066  |
| AP4E1    | 103.1 | 100.0% | 99.0%  | Stuttering, familial persistent, 1, 184450<br>Spastic paraplegia 51, autosomal recessive, 613744  |
| AP4M1    | 140.7 | 99.9%  | 98.6%  | Spastic paraplegia 50, autosomal recessive, 612936  |
| AP4S1    | 66.4  | 77.7%  | 70.3%  | Spastic paraplegia 52, autosomal recessive, 614067  |
| APC2     | 142.2 | 100.0% | 99.6%  | ?Sotos syndrome 3, 617169<br>Cortical dysplasia, complex, with other brain malformations 10, 618677   |
| APOPT1   | 80.4  | 82.1%  | 82.1%  | Mitochondrial complex IV deficiency, 220110   |
| APT X    | 99.2  | 94.5%  | 91.6%  | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920  |
| ARCN1    | 142.5 | 96.8%  | 96.6%  | Short stature, rhizomelic, with microcephaly, micrognathia, and developmental delay, 617164   |
| ARFGEF2  | 129.2 | 99.9%  | 98.9%  | Periventricular heterotopia with microcephaly, 608097   |
| ARG1     | 158.2 | 100.0% | 100.0% | Argininemia, 207800   |
| ARHGAP31 | 151.5 | 99.9%  | 99.1%  | Adams-Oliver syndrome 1, 100300   |
| ARHGEF6  | 112.9 | 99.0%  | 94.9%  | No OMIM Disease ID  |
| ARHGEF9  | 52.4  | 76.3%  | 72.8%  | Epileptic encephalopathy, early infantile, 8, 300607  |
| ARID1A   | 145.9 | 99.7%  | 98.9%  | Coffin-Siris syndrome 2, 614607   |
| ARID1B   | 150.6 | 99.5%  | 99.3%  | Coffin-Siris syndrome 1, 135900   |
| ARID2    | 158.2 | 99.9%  | 98.5%  | Coffin-Siris syndrome 6, 617808   |
| ARL13B   | 98.7  | 100.0% | 99.7%  | Joubert syndrome 8, 612291  |
| ARL6     | 91.8  | 99.9%  | 97.7%  | ?Retinitis pigmentosa 55, 613575<br>Bardet-Biedl syndrome 3, 600151   |
| ARMC9    | 129.0 | 100.0% | 99.4%  | Joubert syndrome 30, 617622   |
| ARSA     | 154.9 | 100.0% | 100.0% | Metachromatic leukodystrophy, 250100  |
| ARSE     | 83.5  | 98.5%  | 91.1%  | Chondrodysplasia punctata, X-linked recessive, 302950   |
| ARV1     | 108.7 | 100.0% | 99.7%  | Epileptic encephalopathy, early infantile, 38, 617020   |
| ARX      | 58.2  | 90.9%  | 83.3%  | Proud syndrome, 300004<br>Lissencephaly, X-linked 2, 300215<br>Partington syndrome, 309510<br>Epileptic encephalopathy, early infantile, 1, 308350<br>Mental retardation, X-linked 29 and others, 300419<br>Hydranencephaly with abnormal genitalia, 300215 |
| ASAH1    | 124.7 | 99.6%  | 96.8%  | Farber lipogranulomatosis, 228000<br>Spinal muscular atrophy with progressive myoclonic epilepsy, 159950  |
| ASH1L    | 146.8 | 98.7%  | 98.4%  | Mental retardation, autosomal dominant 52, 617796   |
| ASL      | 135.7 | 99.9%  | 99.2%  | Argininosuccinic aciduria, 207900   |
| ASNS     | 81.9  | 97.9%  | 91.0%  | Asparagine synthetase deficiency, 615574  |

|          |       |        |        |  |
|----------|-------|--------|--------|--|
| ASPA     | 118.0 | 99.9%  | 96.9%  | Canavan disease, 271900  |
| ASPM     | 111.3 | 99.7%  | 97.8%  | Microcephaly 5, primary, autosomal recessive, 608716   |
| ASS1     | 106.1 | 95.4%  | 88.7%  | Citrullinemia, 215700  |
| ASXL1    | 141.0 | 100.0% | 99.6%  | Bohring-Opitz syndrome, 605039<br>Myelodysplastic syndrome, somatic, 614286  |
| ASXL2    | 150.0 | 99.4%  | 98.2%  | Shashi-Pena syndrome, 617190   |
| ASXL3    | 141.2 | 99.8%  | 99.1%  | Bainbridge-Ropers syndrome, 615485   |
| ATAD1    | 63.3  | 98.8%  | 91.0%  | Hyperekplexia 4, 618011  |
| ATAD3A   | 100.8 | 93.8%  | 88.8%  | Harel-Yoon syndrome, 617183  |
| ATIC     | 114.9 | 100.0% | 99.9%  | AICA-ribosiduria due to ATIC deficiency, 608688  |
| ATL1     | 136.1 | 100.0% | 99.4%  | Spastic paraplegia 3A, autosomal dominant, 182600<br>Neuropathy, hereditary sensory, type ID, 613708                               |
| ATN1     | 175.9 | 99.9%  | 99.2%  | Dentatorubral-pallidoluysian atrophy, 125370<br>Congenital hypotonia, epilepsy, developmental delay, and digital anomalies, 618494 |
| ATP1A1   | 114.1 | 100.0% | 99.7%  | Charcot-Marie-Tooth disease, axonal, type 2DD, 618036<br>Hypomagnesemia, seizures, and mental retardation 2, 618314                |
| ATP1A2   | 173.7 | 100.0% | 99.8%  | Migraine, familial hemiplegic, 2, 602481<br>Migraine, familial basilar, 602481<br>Alternating hemiplegia of childhood 1, 104290    |
| ATP1A3   | 173.9 | 100.0% | 100.0% | CAPOS syndrome, 601338<br>Alternating hemiplegia of childhood 2, 614820<br>Dystonia-12, 128235                                     |
| ATP2A2   | 150.4 | 100.0% | 99.9%  | Acrokeratosis verruciformis, 101900<br>Darier disease, 124200  |
| ATP6AP2  | 45.5  | 89.4%  | 67.3%  | Mental retardation, X-linked, syndromic, Hedera type, 300423<br>?Parkinsonism with spasticity, X-linked, 300911                    |
| ATP6V0A2 | 120.5 | 100.0% | 99.6%  | Wrinkly skin syndrome, 278250<br>Cutis laxa, autosomal recessive, type IIA, 219200   |
| ATP6V1A  | 133.1 | 99.8%  | 97.3%  | Epileptic encephalopathy, infantile or early childhood, 3, 618012<br>Cutis laxa, autosomal recessive, type IID, 617403             |
| ATP6V1B2 | 125.1 | 99.9%  | 99.1%  | Zimmermann-Laband syndrome 2, 616455<br>Deafness, congenital, with onychodystrophy, autosomal dominant, 124480                     |
| ATP7A    | 109.4 | 99.7%  | 97.2%  | Occipital horn syndrome, 304150<br>Menkes disease, 309400<br>Spinal muscular atrophy, distal, X-linked 3, 300489                   |
| ATP8A2   | 118.4 | 100.0% | 99.7%  | ?Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4, 615268  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| ATR      | 142.1 | 99.9%  | 98.9%  | Seckel syndrome 1, 210600<br>?Cutaneous telangiectasia and cancer syndrome, familial, 614564  |
| ATRX     | 86.2  | 99.1%  | 95.1%  | Alpha-thalassemia/mental retardation syndrome, 301040<br>Alpha-thalassemia myelodysplasia syndrome, somatic, 300448<br>Mental retardation-hypotonic facies syndrome, X-linked, 309580 |
| AUH      | 135.7 | 100.0% | 99.8%  | 3-methylglutaconic aciduria, type I, 250950   |
| AUTS2    | 143.1 | 99.8%  | 98.7%  | Mental retardation, autosomal dominant 26, 615834   |
| AVPR2    | 150.2 | 100.0% | 99.8%  | Nephrogenic syndrome of inappropriate antidiuresis, 300539<br>Diabetes insipidus, nephrogenic, 304800   |
| B3GALNT2 | 94.8  | 93.1%  | 91.1%  | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181  |
| B3GALT6  | 96.5  | 87.5%  | 80.2%  | Ehlers-Danlos syndrome, spondylodysplastic type, 2, 615349<br>Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640                           |
| B3GLCT   | 97.3  | 100.0% | 99.7%  | Peters-plus syndrome, 261540  |
| B4GALNT1 | 164.9 | 99.9%  | 98.3%  | Spastic paraplegia 26, autosomal recessive, 609195  |
| B4GALT7  | 138.9 | 100.0% | 99.1%  | Ehlers-Danlos syndrome, spondylodysplastic type, 1, 130070  |
| B4GAT1   | 153.5 | 100.0% | 100.0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287   |
| BAZ2B    | 129.7 | 99.9%  | 98.9%  | No OMIM Disease ID  |
| BBS1     | 156.1 | 100.0% | 100.0% | Bardet-Biedl syndrome 1, 209900   |
| BBS10    | 156.7 | 100.0% | 100.0% | Bardet-Biedl syndrome 10, 615987  |
| BBS12    | 193.6 | 100.0% | 100.0% | Bardet-Biedl syndrome 12, 615989  |
| BBS2     | 153.3 | 100.0% | 99.7%  | Bardet-Biedl syndrome 2, 615981<br>Retinitis pigmentosa 74, 616562  |
| BBS4     | 113.2 | 100.0% | 98.4%  | Bardet-Biedl syndrome 4, 615982   |
| BBS5     | 94.9  | 98.4%  | 92.3%  | Bardet-Biedl syndrome 5, 615983   |
| BBS7     | 136.8 | 99.0%  | 95.3%  | Bardet-Biedl syndrome 7, 615984   |
| BBS9     | 113.2 | 98.8%  | 94.8%  | Bardet-Biedl syndrome 9, 615986   |
| BCAP31   | 78.0  | 93.9%  | 81.2%  | Deafness, dystonia, and cerebral hypomyelination, 300475  |
| BCKDHA   | 193.6 | 100.0% | 99.8%  | Maple syrup urine disease, type Ia, 248600  |
| BCKDHB   | 122.4 | 97.8%  | 90.2%  | Maple syrup urine disease, type Ib, 248600  |
| BCKDK    | 223.0 | 100.0% | 100.0% | Branched-chain ketoacid dehydrogenase kinase deficiency, 614923   |
| BCL11A   | 160.4 | 99.6%  | 98.0%  | Dias-Logan syndrome, 617101   |
| BCL11B   | 147.9 | 100.0% | 99.3%  | Immunodeficiency 49, 617237<br>Intellectual developmental disorder with dysmorphic facies, speech delay, and T-cell abnormalities, 618092   |
| BCOR     | 109.0 | 99.2%  | 96.2%  | Microphthalmia, syndromic 2, 300166   |
| BCORL1   | 162.3 | 99.9%  | 98.5%  | Shukla-Vernon syndrome, 301029  |
| BCS1L    | 160.0 | 100.0% | 100.0% | Leigh syndrome, 256000<br>GRACILE syndrome, 603358  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
|          |       |        |        | Bjornstad syndrome, 262000<br>Mitochondrial complex III deficiency, nuclear type 1, 124000  |
| BLM      | 111.3 | 99.9%  | 98.1%  | Bloom syndrome, 210900  |
| BOLA3    | 50.9  | 99.8%  | 94.6%  | Multiple mitochondrial dysfunctions syndrome 2 with hyperglycinemia, 614299   |
| BPTF     | 144.9 | 96.6%  | 94.9%  | Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, 617755  |
| BRAF     | 71.0  | 91.7%  | 79.4%  | Noonan syndrome 7, 613706<br>Cardiofaciocutaneous syndrome, 115150<br>Adenocarcinoma of lung, somatic, 211980<br>LEOPARD syndrome 3, 613707<br>Non-small cell lung cancer, somatic, 0<br>Melanoma, malignant, somatic, 0<br>Colorectal cancer, somatic, 0 |
| BRAT1    | 155.4 | 100.0% | 99.6%  | Rigidity and multifocal seizure syndrome, lethal neonatal, 614498<br>Neurodevelopmental disorder with cerebellar atrophy and with or without seizures, 618056   |
| BRF1     | 120.2 | 99.9%  | 98.8%  | Cerebellofaciodental syndrome, 616202   |
| BRPF1    | 174.8 | 100.0% | 100.0% | Intellectual developmental disorder with dysmorphic facies and ptosis, 617333   |
| BRSK2    | 137.2 | 100.0% | 99.1%  | No OMIM Disease ID  |
| BRWD3    | 103.5 | 98.9%  | 95.1%  | Mental retardation, X-linked 93, 300659   |
| BSCL2    | 112.9 | 100.0% | 99.9%  | Lipodystrophy, congenital generalized, type 2, 269700<br>Silver spastic paraplegia syndrome, 270685<br>Neuropathy, distal hereditary motor, type VA, 600794<br>Encephalopathy, progressive, with or without lipodystrophy, 615924                         |
| BTD      | 135.6 | 100.0% | 99.8%  | Biotinidase deficiency, 253260  |
| BUB1B    | 121.6 | 99.9%  | 99.0%  | Colorectal cancer, somatic, 114500<br>Mosaic variegated aneuploidy syndrome 1, 257300   |
| C12orf4  | 126.3 | 100.0% | 99.7%  | Mental retardation, autosomal recessive 66, 618221  |
| C12orf57 | 159.8 | 100.0% | 100.0% | Temtamy syndrome, 218340  |
| C12orf65 | 112.4 | 100.0% | 99.8%  | Spastic paraplegia 55, autosomal recessive, 615035<br>Combined oxidative phosphorylation deficiency 7, 613559   |
| C2CD3    | 121.4 | 95.8%  | 95.3%  | Orofaciodigital syndrome XIV, 615948  |
| C5orf42  | 122.3 | 99.7%  | 97.4%  | Joubert syndrome 17, 614615<br>Orofaciodigital syndrome VI, 277170  |
| CA2      | 141.8 | 100.0% | 99.9%  | Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730   |
| CA5A     | 99.0  | 99.9%  | 97.2%  | Hyperammonemia due to carbonic anhydrase VA deficiency, 615751  |
| CA8      | 112.7 | 99.3%  | 96.2%  | Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227   |
| CACNA1A  | 101.2 | 98.2%  | 96.2%  | Spinocerebellar ataxia 6, 183086<br>Epileptic encephalopathy, early infantile, 42, 617106   |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
|         |       |        |        | Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500<br>Episodic ataxia, type 2, 108500<br>Migraine, familial hemiplegic, 1, 141500          |
| CACNA1B | 147.4 | 99.8%  | 98.6%  | Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, 618497  |
| CACNA1C | 151.7 | 99.9%  | 99.4%  | Timothy syndrome, 601005<br>Long QT syndrome 8, 618447<br>Brugada syndrome 3, 611875   |
| CACNA1D | 135.3 | 98.0%  | 97.8%  | Primary aldosteronism, seizures, and neurologic abnormalities, 615474<br>Sinoatrial node dysfunction and deafness, 614896  |
| CACNA1E | 129.3 | 100.0% | 99.5%  | Epileptic encephalopathy, early infantile, 69, 618285  |
| CACNA1G | 165.6 | 100.0% | 99.9%  | Spinocerebellar ataxia 42, 616795<br>Spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits, 618087  |
| CAD     | 147.4 | 100.0% | 99.6%  | Epileptic encephalopathy, early infantile, 50, 616457  |
| CAMK2A  | 125.8 | 100.0% | 99.9%  | ?Mental retardation, autosomal recessive 63, 618095<br>Mental retardation, autosomal dominant 53, 617798   |
| CAMK2B  | 122.1 | 100.0% | 100.0% | Mental retardation, autosomal dominant 54, 617799  |
| CAMK2G  | 114.9 | 99.9%  | 99.1%  | Mental retardation, autosomal dominant 59, 618522  |
| CAMTA1  | 197.4 | 100.0% | 99.9%  | Cerebellar ataxia, nonprogressive, with mental retardation, 614756   |
| CANT1   | 158.4 | 100.0% | 100.0% | Desbuquois dysplasia 1, 251450<br>Epiphyseal dysplasia, multiple, 7, 617719  |
| CARS2   | 138.8 | 100.0% | 100.0% | Combined oxidative phosphorylation deficiency 27, 616672   |
| CASK    | 84.5  | 99.4%  | 94.0%  | Mental retardation, with or without nystagmus, 300422<br>Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749<br>FG syndrome 4, 300422 |
| CBL     | 131.1 | 97.4%  | 97.1%  | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563<br>?Juvenile myelomonocytic leukemia, 607785                                  |
| CBS     | 136.4 | 100.0% | 99.3%  | Homocystinuria, B6-responsive and nonresponsive types, 236200<br>Thrombosis, hyperhomocysteinemic, 236200  |
| CC2D1A  | 147.9 | 100.0% | 99.8%  | Mental retardation, autosomal recessive 3, 608443  |
| CC2D2A  | 112.6 | 99.0%  | 97.0%  | Meckel syndrome 6, 612284<br>Joubert syndrome 9, 612285<br>COACH syndrome, 216360  |
| CCBE1   | 80.9  | 99.8%  | 98.6%  | Hennekam lymphangiectasia-lymphedema syndrome 1, 235510  |
| CCDC115 | 89.9  | 88.5%  | 87.0%  | Congenital disorder of glycosylation, type Ilo, 616828   |
| CCDC174 | 126.5 | 99.3%  | 96.6%  | Hypotonia, infantile, with psychomotor retardation, 616816   |
| CCDC22  | 105.7 | 99.0%  | 95.5%  | Ritscher-Schinzel syndrome 2, 300963   |
| CCDC47  | 144.5 | 99.0%  | 96.4%  | Trichohepatoneurodevelopmental syndrome, 618268  |



|          |       |        |        |  |
|----------|-------|--------|--------|--|
| CCDC88A  | 90.3  | 99.3%  | 96.4%  | ?PEHO syndrome-like, 617507  |
| CCDC88C  | 119.2 | 100.0% | 99.7%  | ?Spinocerebellar ataxia 40, 616053<br>Hydrocephalus, congenital, 1, 236600   |
| CCND2    | 147.6 | 100.0% | 100.0% | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938   |
| CCNK     | 92.2  | 91.0%  | 87.3%  | ?Intellectual developmental disorder with hypertelorism and distinctive facies, 618147   |
| CDC42    | 89.8  | 98.1%  | 90.1%  | Takenouchi-Kosaki syndrome, 616737   |
| CDC6     | 142.2 | 100.0% | 99.7%  | ?Meier-Gorlin syndrome 5, 613805   |
| CDH11    | 131.7 | 100.0% | 100.0% | Elsahy-Waters syndrome, 211380   |
| CDH15    | 173.0 | 100.0% | 99.9%  | Mental retardation, autosomal dominant 3, 612580   |
| CDK10    | 141.9 | 100.0% | 100.0% | Al Kaissi syndrome, 617694   |
| CDK13    | 133.2 | 100.0% | 99.2%  | Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder, 617360  |
| CDK5RAP2 | 109.3 | 99.8%  | 99.0%  | Microcephaly 3, primary, autosomal recessive, 604804   |
| CDK8     | 141.7 | 99.5%  | 95.5%  | No OMIM Disease ID   |
| CDKL5    | 102.7 | 95.0%  | 92.9%  | Epileptic encephalopathy, early infantile, 2, 300672   |
| CDKN1C   | 116.5 | 93.6%  | 84.7%  | IMAGE syndrome, 614732<br>Beckwith-Wiedemann syndrome, 130650  |
| CDON     | 110.7 | 99.9%  | 99.0%  | Holoprosencephaly 11, 614226   |
| CENPF    | 143.9 | 99.8%  | 98.7%  | Stromme syndrome, 243605   |
| CENPJ    | 135.8 | 100.0% | 99.4%  | Microcephaly 6, primary, autosomal recessive, 608393<br>?Seckel syndrome 4, 613676   |
| CEP104   | 108.8 | 99.3%  | 97.8%  | Joubert syndrome 25, 616781  |
| CEP120   | 131.3 | 100.0% | 99.6%  | Joubert syndrome 31, 617761<br>Short-rib thoracic dysplasia 13 with or without polydactyly, 616300   |
| CEP135   | 88.3  | 99.1%  | 92.0%  | Microcephaly 8, primary, autosomal recessive, 614673   |
| CEP152   | 145.3 | 99.6%  | 97.8%  | Microcephaly 9, primary, autosomal recessive, 614852<br>Seckel syndrome 5, 613823  |
| CEP290   | 77.6  | 96.9%  | 88.7%  | ?Bardet-Biedl syndrome 14, 615991<br>Leber congenital amaurosis 10, 611755<br>Senior-Loken syndrome 6, 610189<br>Meckel syndrome 4, 611134<br>Joubert syndrome 5, 610188 |
| CEP41    | 79.1  | 98.7%  | 94.4%  | Joubert syndrome 15, 614464  |
| CEP57    | 84.9  | 99.3%  | 92.8%  | Mosaic variegated aneuploidy syndrome 2, 614114  |
| CEP83    | 103.3 | 99.8%  | 96.2%  | Nephronophthisis 18, 615862  |
| CEP89    | 130.0 | 98.2%  | 95.5%  | No OMIM disease ID   |
| CHAMP1   | 181.4 | 100.0% | 100.0% | Mental retardation, autosomal dominant 40, 616579  |
| CHD1     | 104.2 | 97.7%  | 90.7%  | Pilarowski-Bjornsson syndrome, 617682  |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| CHD2    | 126.1 | 99.4%  | 99.1%  | Epileptic encephalopathy, childhood-onset, 615369   |
| CHD3    | 101.6 | 98.4%  | 95.1%  | Snijders Blok-Campeau syndrome, 618205  |
| CHD4    | 117.3 | 100.0% | 99.9%  | Sifrim-Hitz-Weiss syndrome, 617159  |
| CHD7    | 143.6 | 100.0% | 99.5%  | CHARGE syndrome, 214800<br>Hypogonadotropic hypogonadism 5 with or without anosmia, 612370                          |
| CHD8    | 133.1 | 100.0% | 99.9%  | No OMIM disease ID  |
| CHKB    | 126.8 | 100.0% | 100.0% | Muscular dystrophy, congenital, megaconial type, 602541   |
| CHMP1A  | 133.0 | 100.0% | 99.8%  | Pontocerebellar hypoplasia, type 8, 614961  |
| CHRNA4  | 125.3 | 100.0% | 99.3%  | Epilepsy, nocturnal frontal lobe, 1, 600513   |
| CIC     | 83.4  | 64.8%  | 63.4%  | Mental retardation, autosomal dominant 45, 617600   |
| CIT     | 106.3 | 100.0% | 98.9%  | Microcephaly 17, primary, autosomal recessive, 617090   |
| CKAP2L  | 154.2 | 99.9%  | 98.9%  | Filippi syndrome, 272440  |
| CLCN4   | 111.7 | 99.9%  | 98.8%  | Raynaud-Claes syndrome, 300114  |
| CLIC2   | 72.0  | 100.0% | 98.2%  | ?Mental retardation, X-linked, syndromic 32, 300886   |
| CLIP1   | 122.0 | 99.9%  | 99.1%  | No OMIM Disease ID  |
| CLN3    | 123.4 | 92.5%  | 92.2%  | Ceroid lipofuscinosis, neuronal, 3, 204200  |
| CLN5    | 139.4 | 100.0% | 99.5%  | Ceroid lipofuscinosis, neuronal, 5, 256731  |
| CLN6    | 141.7 | 100.0% | 100.0% | Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300<br>Ceroid lipofuscinosis, neuronal, 6, 601780       |
| CLN8    | 156.2 | 83.5%  | 83.5%  | Ceroid lipofuscinosis, neuronal, 8, 600143<br>Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 |
| CLP1    | 146.0 | 100.0% | 100.0% | Pontocerebellar hypoplasia, type 10, 615803   |
| CLPB    | 135.3 | 99.7%  | 97.4%  | 3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271               |
| CLTC    | 154.5 | 100.0% | 99.8%  | Mental retardation, autosomal dominant 56, 617854   |
| CNKS2   | 88.5  | 98.6%  | 92.0%  | Mental retardation, X-linked, syndromic, Houge type, 301008   |
| CNNM2   | 222.5 | 100.0% | 100.0% | Hypomagnesemia 6, renal, 613882<br>Hypomagnesemia, seizures, and mental retardation, 616418                         |
| CNOT1   | 127.6 | 100.0% | 99.8%  | Holoprosencephaly 12, with or without pancreatic agenesis, 618500   |
| CNOT2   | 130.4 | 100.0% | 99.8%  | Intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, 618608   |
| CNOT3   | 162.6 | 100.0% | 100.0% | Intellectual developmental disorder with speech delay, autism, and dysmorphic facies, 618672                        |
| CNPY3   | 83.9  | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 60, 617929   |
| CNTNAP2 | 129.8 | 100.0% | 99.8%  | Pitt-Hopkins like syndrome 1, 610042<br>Cortical dysplasia-focal epilepsy syndrome, 610042                          |
| COASY   | 190.6 | 100.0% | 100.0% | Pontocerebellar hypoplasia, type 12, 618266<br>Neurodegeneration with brain iron accumulation 6, 615643             |
| COG1    | 117.9 | 100.0% | 99.9%  | Congenital disorder of glycosylation, type IIg, 611209  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| COG4     | 99.0  | 100.0% | 99.7%  | Saul-Wilson syndrome, 618150<br>Congenital disorder of glycosylation, type IIj, 613489  |
| COG5     | 123.1 | 99.8%  | 97.9%  | Congenital disorder of glycosylation, type IIi, 613612  |
| COG6     | 87.3  | 98.6%  | 95.6%  | Shaheen syndrome, 615328<br>Congenital disorder of glycosylation, type III, 614576  |
| COG7     | 111.8 | 100.0% | 99.9%  | Congenital disorder of glycosylation, type IIe, 608779  |
| COG8     | 160.1 | 100.0% | 98.6%  | Congenital disorder of glycosylation, type IIh, 611182  |
| COL4A1   | 100.3 | 99.8%  | 98.0%  | ?Retinal arteries, tortuosity of, 180000<br>Brain small vessel disease with or without ocular anomalies, 175780<br>Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773<br>Microangiopathy and leukoencephalopathy, pontine, autosomal dominant, 618564 |
| COL4A2   | 118.1 | 100.0% | 99.4%  | Brain small vessel disease 2, 614483  |
| COL4A3BP | 132.6 | 99.6%  | 97.3%  | Mental retardation, autosomal dominant 34, 616351   |
| COLEC11  | 197.8 | 100.0% | 100.0% | 3MC syndrome 2, 265050  |
| COQ2     | 107.7 | 97.7%  | 97.0%  | Coenzyme Q10 deficiency, primary, 1, 607426   |
| COQ4     | 116.2 | 91.7%  | 90.8%  | Coenzyme Q10 deficiency, primary, 7, 616276   |
| COQ8A    | 177.7 | 100.0% | 100.0% | Coenzyme Q10 deficiency, primary, 4, 612016   |
| COQ9     | 78.6  | 99.9%  | 98.5%  | Coenzyme Q10 deficiency, primary, 5, 614654   |
| COX10    | 232.8 | 100.0% | 100.0% | Mitochondrial complex IV deficiency, 220110<br>Leigh syndrome due to mitochondrial COX4 deficiency, 256000  |
| COX15    | 90.4  | 99.9%  | 98.7%  | Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119<br>Leigh syndrome due to cytochrome c oxidase deficiency, 256000   |
| COX6B1   | 143.0 | 100.0% | 100.0% | Mitochondrial complex IV deficiency, 220110   |
| CPLX1    | 119.2 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 63, 617976   |
| CPS1     | 133.4 | 100.0% | 99.9%  | Carbamoylphosphate synthetase I deficiency, 237300  |
| CRADD    | 120.5 | 100.0% | 99.0%  | Mental retardation, autosomal recessive 34, with variant lissencephaly, 614499  |
| CRBN     | 122.9 | 88.2%  | 87.4%  | Mental retardation, autosomal recessive 2, 607417   |
| CREBBP   | 120.9 | 99.6%  | 97.3%  | Rubinstein-Taybi syndrome 1, 180849<br>Menke-Hennekam syndrome 1, 618332  |
| CRLF1    | 140.3 | 93.9%  | 91.4%  | Cold-induced sweating syndrome 1, 272430  |
| CSNK2A1  | 106.2 | 94.0%  | 89.7%  | Okur-Chung neurodevelopmental syndrome, 617062  |
| CSNK2B   | 136.5 | 100.0% | 100.0% | No OMIM Disease ID  |
| CSPP1    | 117.4 | 100.0% | 99.4%  | Joubert syndrome 21, 615636   |
| CSTB     | 74.8  | 99.1%  | 93.0%  | Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800  |
| CTBP1    | 111.3 | 95.7%  | 88.6%  | Hypotonia, ataxia, developmental delay, and tooth enamel defect syndrome, 617915  |
| CTC1     | 113.5 | 100.0% | 99.6%  | Cerebroretinal microangiopathy with calcifications and cysts, 612199  |
| CTCF     | 131.3 | 100.0% | 99.1%  | Mental retardation, autosomal dominant 21, 615502   |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| CTDP1   | 141.7 | 96.2%  | 88.2%  | Congenital cataracts, facial dysmorphism, and neuropathy, 604168  |
| CTNNA2  | 110.0 | 100.0% | 99.7%  | Cortical dysplasia, complex, with other brain malformations 9, 618174   |
| CTNNB1  | 129.5 | 100.0% | 100.0% | Ovarian cancer, somatic, 167000<br>Colorectal cancer, somatic, 114500<br>Medulloblastoma, somatic, 155255<br>Hepatocellular carcinoma, somatic, 114550<br>Pilomatricoma, somatic, 132600<br>Neurodevelopmental disorder with spastic diplegia and visual defects, 615075<br>Exudative vitreoretinopathy 7, 617572 |
| CTNND2  | 104.9 | 97.9%  | 93.9%  | No OMIM Disease ID  |
| CTSA    | 146.1 | 100.0% | 100.0% | Galactosialidosis, 256540   |
| CTSD    | 187.3 | 100.0% | 99.0%  | Ceroid lipofuscinosis, neuronal, 10, 610127   |
| CTTNBP2 | 119.0 | 99.7%  | 97.9%  | No OMIM Disease ID  |
| CUL4B   | 75.8  | 97.7%  | 88.2%  | Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354   |
| CUX1    | 128.7 | 99.0%  | 96.5%  | Global developmental delay with or without impaired intellectual development, 618330  |
| CUX2    | 134.5 | 100.0% | 99.4%  | Epileptic encephalopathy, early infantile, 67, 618141   |
| CWC27   | 82.5  | 99.8%  | 97.3%  | Retinitis pigmentosa with or without skeletal anomalies, 250410   |
| CWF19L1 | 103.5 | 100.0% | 99.1%  | Spinocerebellar ataxia, autosomal recessive 17, 616127  |
| CXorf56 | 74.7  | 99.5%  | 93.2%  | ?Mental retardation, X-linked 107, 301013   |
| CYB5R3  | 163.2 | 99.6%  | 98.5%  | Methemoglobinemia, type I, 250800<br>Methemoglobinemia, type II, 250800   |
| CYFIP2  | 122.2 | 99.9%  | 98.7%  | Epileptic encephalopathy, early infantile, 65, 618008   |
| CYP27A1 | 184.4 | 100.0% | 99.8%  | Cerebrotendinous xanthomatosis, 213700  |
| CYP2U1  | 139.8 | 99.1%  | 96.8%  | Spastic paraplegia 56, autosomal recessive, 615030  |
| D2HGDH  | 157.7 | 100.0% | 99.8%  | D-2-hydroxyglutaric aciduria, 600721  |
| DAG1    | 205.3 | 100.0% | 100.0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 9, 616538  |
| DARS    | 121.4 | 99.9%  | 99.0%  | Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281   |
| DARS2   | 125.4 | 100.0% | 98.6%  | Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105   |
| DBT     | 109.6 | 99.7%  | 96.9%  | Maple syrup urine disease, type II, 248600  |
| DCAF17  | 87.5  | 100.0% | 99.2%  | Woodhouse-Sakati syndrome, 241080   |
| DCC     | 119.4 | 100.0% | 99.9%  | Esophageal carcinoma, somatic, 133239<br>Gaze palsy, familial horizontal, with progressive scoliosis, 2, 617542<br>Mirror movements 1 and/or agenesis of the corpus callosum, 157600<br>Colorectal cancer, somatic, 114500  |
| DCHS1   | 164.5 | 100.0% | 100.0% | Mitral valve prolapse 2, 607829<br>Van Maldergem syndrome 1, 601390   |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| DCPS    | 140.6 | 100.0% | 99.9%  | Al-Raqad syndrome, 616459   |
| DCX     | 93.7  | 99.8%  | 98.9%  | Subcortical laminar heterotopia, X-linked, 300067<br>Lissencephaly, X-linked, 300067  |
| DDC     | 100.3 | 99.4%  | 96.2%  | Aromatic L-amino acid decarboxylase deficiency, 608643  |
| DDHD2   | 130.8 | 100.0% | 99.7%  | Spastic paraplegia 54, autosomal recessive, 615033  |
| DDX11   | 108.3 | 88.3%  | 82.2%  | Warsaw breakage syndrome, 613398  |
| DDX3X   | 74.5  | 86.2%  | 82.8%  | Mental retardation, X-linked 102, 300958  |
| DDX59   | 143.3 | 100.0% | 99.7%  | Orofaciodigital syndrome V, 174300  |
| DDX6    | 58.0  | 95.7%  | 81.6%  | Intellectual developmental disorder with impaired language and dysmorphic facies, 618653  |
| DEAF1   | 124.1 | 100.0% | 99.1%  | Mental retardation, autosomal dominant 24, 615828<br>?Dyskinesia, seizures, and intellectual developmental disorder, 617171   |
| DEGS1   | 150.2 | 100.0% | 100.0% | Leukodystrophy, hypomyelinating, 18, 618404   |
| DENND5A | 101.5 | 99.8%  | 98.9%  | Epileptic encephalopathy, early infantile, 49, 617281   |
| DEPDC5  | 129.9 | 100.0% | 99.8%  | Epilepsy, familial focal, with variable foci 1, 604364  |
| DHCR24  | 170.7 | 100.0% | 99.9%  | Desmosterolosis, 602398   |
| DHCR7   | 158.7 | 100.0% | 100.0% | Smith-Lemli-Opitz syndrome, 270400  |
| DHDDS   | 84.5  | 97.3%  | 94.0%  | Retinitis pigmentosa 59, 613861<br>?Congenital disorder of glycosylation, type 1bb, 613861<br>Developmental delay and seizures with or without movement abnormalities, 617836 |
| DHFR    | 48.6  | 92.6%  | 80.9%  | Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839  |
| DHPS    | 126.4 | 100.0% | 100.0% | Neurodevelopmental disorder with seizures and speech and walking impairment, 618480   |
| DHTKD1  | 127.4 | 99.9%  | 99.0%  | 2-aminoadipic 2-oxoadipic aciduria, 204750<br>?Charcot-Marie-Tooth disease, axonal, type 2Q, 615025   |
| DHX30   | 178.6 | 100.0% | 100.0% | Neurodevelopmental disorder with severe motor impairment and absent language, 617804  |
| DIAPH1  | 104.4 | 100.0% | 99.8%  | Seizures, cortical blindness, microcephaly syndrome, 616632<br>Deafness, autosomal dominant 1, 124900   |
| DIP2B   | 131.4 | 100.0% | 100.0% | Mental retardation, FRA12A type, 136630   |
| DIS3L2  | 151.0 | 100.0% | 99.9%  | Perlman syndrome, 267000  |
| DKC1    | 93.9  | 99.7%  | 98.0%  | Dyskeratosis congenita, X-linked, 305000  |
| DLD     | 117.2 | 100.0% | 99.9%  | Dihydrolipoamide dehydrogenase deficiency, 246900   |
| DLG3    | 84.8  | 99.3%  | 94.6%  | Mental retardation, X-linked 90, 300850   |
| DLG4    | 158.8 | 100.0% | 100.0% | No OMIM Disease ID  |
| DMD     | 107.5 | 99.6%  | 97.9%  | Cardiomyopathy, dilated, 3B, 302045<br>Becker muscular dystrophy, 300376<br>Duchenne muscular dystrophy, 310200   |
| DMPK    | 166.2 | 100.0% | 99.9%  | Myotonic dystrophy 1, 160900  |
| DNAJC12 | 144.7 | 87.4%  | 87.4%  | Hyperphenylalaninemia, mild, non-BH4-deficient, 617384  |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| DNAJC19 | 92.5  | 99.1%  | 90.4%  | 3-methylglutaconic aciduria, type V, 610198   |
| DNM1    | 151.2 | 94.9%  | 93.3%  | Epileptic encephalopathy, early infantile, 31, 616346   |
| DNMT3A  | 132.4 | 99.9%  | 98.7%  | Acute myeloid leukemia, somatic, 601626<br>Tatton-Brown-Rahman syndrome, 615879   |
| DNMT3B  | 125.5 | 100.0% | 99.9%  | Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860  |
| DOCK3   | 118.4 | 100.0% | 99.5%  | Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, 618292   |
| DOCK6   | 132.3 | 99.6%  | 98.9%  | Adams-Oliver syndrome 2, 614219   |
| DOCK7   | 118.3 | 99.6%  | 97.8%  | Epileptic encephalopathy, early infantile, 23, 615859   |
| DOLK    | 171.4 | 100.0% | 100.0% | Congenital disorder of glycosylation, type Im, 610768   |
| DONSON  | 92.4  | 99.6%  | 94.7%  | Microcephaly-micromelia syndrome, 251230<br>Microcephaly, short stature, and limb abnormalities, 617604   |
| DPAGT1  | 93.2  | 100.0% | 100.0% | Congenital disorder of glycosylation, type Ij, 608093<br>Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750   |
| DPF2    | 105.3 | 99.9%  | 97.4%  | Coffin-Siris syndrome 7, 618027   |
| DPH1    | 177.3 | 100.0% | 100.0% | Developmental delay with short stature, dysmorphic facial features, and sparse hair, 616901   |
| DPM1    | 134.2 | 95.5%  | 87.7%  | Congenital disorder of glycosylation, type Ie, 608799   |
| DPP6    | 129.8 | 100.0% | 99.8%  | Mental retardation, autosomal dominant 33, 616311   |
| DPYD    | 140.7 | 99.4%  | 96.2%  | Dihydropyrimidine dehydrogenase deficiency, 274270<br>5-fluorouracil toxicity, 274270   |
| DPYS    | 121.4 | 100.0% | 99.9%  | Dihydropyrimidinuria, 222748  |
| DYM     | 102.4 | 97.4%  | 95.7%  | Smith-McCort dysplasia, 607326<br>Dyggve-Melchior-Clausen disease, 223800   |
| DYNC1H1 | 149.0 | 100.0% | 99.8%  | Mental retardation, autosomal dominant 13, 614563<br>Spinal muscular atrophy, lower extremity-predominant 1, AD, 158600<br>Charcot-Marie-Tooth disease, axonal, type 20, 614228 |
| DYNC1I2 | 49.4  | 83.2%  | 67.5%  | Neurodevelopmental disorder with microcephaly and structural brain anomalies, 618492  |
| DYRK1A  | 134.0 | 100.0% | 100.0% | Mental retardation, autosomal dominant 7, 614104  |
| EBF3    | 153.4 | 100.0% | 99.9%  | Hypotonia, ataxia, and delayed development syndrome, 617330   |
| EBP     | 68.9  | 99.8%  | 96.3%  | Chondrodysplasia punctata, X-linked dominant, 302960<br>MEND syndrome, 300960   |
| ECHS1   | 111.6 | 100.0% | 100.0% | Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277  |
| EDC3    | 120.5 | 100.0% | 99.2%  | ?Mental retardation, autosomal recessive 50, 616460   |
| EED     | 83.9  | 98.8%  | 93.6%  | Cohen-Gibson syndrome, 617561   |
| EEF1A2  | 209.4 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 33, 616409<br>Mental retardation, autosomal dominant 38, 616393  |
| EFNB2   | 151.8 | 100.0% | 99.6%  | No OMIM Disease ID  |
| EFTUD2  | 107.1 | 100.0% | 99.5%  | Mandibulofacial dysostosis, Guion-Almeida type, 610536  |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| EHMT1   | 138.4 | 94.7%  | 94.5%  | Kleefstra syndrome 1, 610253  |
| EIF2AK3 | 134.0 | 99.5%  | 96.7%  | Wolcott-Rallison syndrome, 226980   |
| EIF2S3  | 82.9  | 96.7%  | 88.2%  | MEHMO syndrome, 300148  |
| EIF3F   | 67.7  | 99.3%  | 92.9%  | Mental retardation, autosomal recessive 67, 618295  |
| EIF4A3  | 89.6  | 100.0% | 98.9%  | Robin sequence with cleft mandible and limb anomalies, 268305   |
| ELAC2   | 117.1 | 100.0% | 99.5%  | Combined oxidative phosphorylation deficiency 17, 615440  |
| ELOVL4  | 103.3 | 100.0% | 99.6%  | Spinocerebellar ataxia 34, 133190<br>Stargardt disease 3, 600110<br>Ichthyosis, spastic quadriplegia, and mental retardation, 614457  |
| ELP2    | 118.6 | 99.8%  | 97.6%  | Mental retardation, autosomal recessive 58, 617270  |
| EMC1    | 111.0 | 100.0% | 99.2%  | Cerebellar atrophy, visual impairment, and psychomotor retardation, 616875  |
| EML1    | 134.8 | 100.0% | 99.9%  | Band heterotopia, 600348  |
| EMX2    | 175.9 | 100.0% | 100.0% | Schizencephaly, 269160  |
| ENTPD1  | 125.9 | 100.0% | 100.0% | Spastic paraplegia 64, autosomal recessive, 615683  |
| EP300   | 173.3 | 99.7%  | 98.7%  | Rubinstein-Taybi syndrome 2, 613684<br>Menke-Hennekam syndrome 2, 618333<br>Colorectal cancer, somatic, 114500  |
| EPG5    | 111.4 | 99.5%  | 98.3%  | Vici syndrome, 242840   |
| ERCC1   | 91.5  | 100.0% | 98.8%  | Cerebrooculofacioskeletal syndrome 4, 610758  |
| ERCC2   | 139.5 | 100.0% | 99.9%  | Trichothiodystrophy 1, photosensitive, 601675<br>?Cerebrooculofacioskeletal syndrome 2, 610756<br>Xeroderma pigmentosum, group D, 278730  |
| ERCC3   | 95.9  | 99.9%  | 98.7%  | Xeroderma pigmentosum, group B, 610651<br>Trichothiodystrophy 2, photosensitive, 616390   |
| ERCC5   | 130.9 | 100.0% | 99.4%  | Xeroderma pigmentosum, group G/Cockayne syndrome, 278780<br>Xeroderma pigmentosum, group G, 278780<br>Cerebrooculofacioskeletal syndrome 3, 616570  |
| ERCC6   | 161.8 | 100.0% | 100.0% | Cerebrooculofacioskeletal syndrome 1, 214150<br>Cockayne syndrome, type B, 133540<br>Premature ovarian failure 11, 616946<br>UV-sensitive syndrome 1, 600630<br>De Sanctis-Cacchione syndrome, 278800 |
| ERCC8   | 79.9  | 99.0%  | 89.3%  | Cockayne syndrome, type A, 216400<br>UV-sensitive syndrome 2, 614621  |
| ERLIN2  | 119.3 | 100.0% | 99.4%  | Spastic paraplegia 18, autosomal recessive, 611225  |
| ESCO2   | 112.4 | 99.5%  | 96.2%  | Roberts syndrome, 268300<br>SC phocomelia syndrome, 269000  |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| ETFB    | 127.7 | 100.0% | 100.0% | Glutaric acidemia IIB, 231680   |
| ETHE1   | 105.9 | 99.9%  | 97.9%  | Ethylmalonic encephalopathy, 602473   |
| EXOSC2  | 114.1 | 100.0% | 99.9%  | Short stature, hearing loss, retinitis pigmentosa, and distinctive facies, 617763   |
| EXOSC3  | 135.7 | 96.5%  | 87.0%  | Pontocerebellar hypoplasia, type 1B, 614678   |
| EXOSC9  | 133.4 | 99.2%  | 95.0%  | Pontocerebellar hypoplasia, type 1D, 618065   |
| EXTL3   | 200.7 | 100.0% | 100.0% | Immunoskeletal dysplasia with neurodevelopmental abnormalities, 617425  |
| EZH2    | 130.3 | 99.5%  | 98.0%  | Weaver syndrome, 277590   |
| FA2H    | 101.5 | 99.3%  | 95.1%  | Spastic paraplegia 35, autosomal recessive, 612319  |
| FAM126A | 124.1 | 100.0% | 98.9%  | Leukodystrophy, hypomyelinating, 5, 610532  |
| FAM20C  | 165.1 | 100.0% | 100.0% | Raine syndrome, 259775  |
| FAR1    | 72.4  | 97.6%  | 91.9%  | Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154   |
| FARS2   | 169.5 | 100.0% | 100.0% | Spastic paraplegia 77, autosomal recessive, 617046<br>Combined oxidative phosphorylation deficiency 14, 614946  |
| FARSB   | 77.5  | 96.9%  | 93.0%  | Rajab interstitial lung disease with brain calcifications, 613658   |
| FAT4    | 195.5 | 100.0% | 100.0% | Van Maldergem syndrome 2, 615546<br>Hennekam lymphangiectasia-lymphedema syndrome 2, 616006   |
| FBXL3   | 187.9 | 100.0% | 100.0% | Intellectual developmental disorder with short stature, facial anomalies, and speech defects, 606220  |
| FBXL4   | 165.9 | 100.0% | 100.0% | Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471   |
| FBXO11  | 82.9  | 98.5%  | 94.3%  | Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities, 618089   |
| FBXO31  | 123.6 | 100.0% | 98.7%  | ?Mental retardation, autosomal recessive 45, 615979   |
| FGD1    | 93.2  | 98.7%  | 94.4%  | Mental retardation, X-linked syndromic 16, 305400<br>Aarskog-Scott syndrome, 305400   |
| FGF12   | 105.7 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 47, 617166   |
| FGF14   | 225.9 | 100.0% | 100.0% | Spinocerebellar ataxia 27, 609307   |
| FGFR1   | 131.6 | 100.0% | 99.7%  | Pfeiffer syndrome, 101600<br>Jackson-Weiss syndrome, 123150<br>Trigonocephaly 1, 190440<br>Hypogonadotropic hypogonadism 2 with or without anosmia, 147950<br>Hartsfield syndrome, 615465<br>Osteoglophonic dysplasia, 166250<br>Encephalocraniocutaneous lipomatosis, somatic mosaic, 613001 |
| FGFR2   | 118.0 | 97.7%  | 97.1%  | Apert syndrome, 101200<br>Jackson-Weiss syndrome, 123150<br>Saethre-Chotzen syndrome, 101400<br>Gastric cancer, somatic, 613659<br>Scaphocephaly, maxillary retrusion, and mental retardation, 609579<br>Bent bone dysplasia syndrome, 614592   |



|       |       |        |        |  |
|-------|-------|--------|--------|--|
|       |       |        |        | LADD syndrome, 149730<br>Craniofacial-skeletal-dermatologic dysplasia, 101600<br>Pfeiffer syndrome, 101600<br>Crouzon syndrome, 123500<br>Beare-Stevenson cutis gyrata syndrome, 123790<br>Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410<br>Craniosynostosis, nonspecific, 0<br>Scaphocephaly and Axenfeld-Rieger anomaly, 0  |
| FGFR3 | 157.1 | 100.0% | 99.9%  | Muenke syndrome, 602849<br>Nevus, epidermal, somatic, 162900<br>Thanatophoric dysplasia, type II, 187601<br>Bladder cancer, somatic, 109800<br>CATSHL syndrome, 610474<br>Crouzon syndrome with acanthosis nigricans, 612247<br>Hypochondroplasia, 146000<br>LADD syndrome, 149730<br>Achondroplasia, 100800<br>Thanatophoric dysplasia, type I, 187600<br>Colorectal cancer, somatic, 114500<br>Spermatocytic seminoma, somatic, 273300<br>Cervical cancer, somatic, 603956<br>SADDAN, 616482 |
| FH    | 126.0 | 95.9%  | 89.5%  | Fumarase deficiency, 606812<br>Leiomyomatosis and renal cell cancer, 150800  |
| FIBP  | 135.9 | 100.0% | 100.0% | Thauvin-Robinet-Faivre syndrome, 617107  |
| FIGN  | 141.0 | 100.0% | 100.0% | No OMIM Disease ID   |
| FKRP  | 178.0 | 100.0% | 100.0% | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155<br>Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153   |
| FKTN  | 108.0 | 99.9%  | 96.4%  | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588<br>Cardiomyopathy, dilated, 1X, 611615<br>Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800  |
| FLNA  | 156.4 | 100.0% | 99.9%  | Otopalatodigital syndrome, type I, 311300<br>Congenital short bowel syndrome, 300048<br>Otopalatodigital syndrome, type II, 304120<br>Intestinal pseudoobstruction, neuronal, 300048<br>Melnick-Needles syndrome, 309350   |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
|         |       |        |        | Cardiac valvular dysplasia, X-linked, 314400<br>?FG syndrome 2, 300321<br>Heterotopia, periventricular, 1, 300049<br>Terminal osseous dysplasia, 300244<br>Frontometaphyseal dysplasia 1, 305620 |
| FLVCR1  | 154.8 | 100.0% | 99.4%  | Ataxia, posterior column, with retinitis pigmentosa, 609033  |
| FLVCR2  | 131.7 | 100.0% | 100.0% | Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome, 225790   |
| FMN2    | 120.8 | 87.1%  | 84.7%  | Mental retardation, autosomal recessive 47, 616193   |
| FMR1    | 78.1  | 96.3%  | 90.1%  | Premature ovarian failure 1, 311360<br>Fragile X tremor/ataxia syndrome, 300623<br>Fragile X syndrome, 300624  |
| FOLR1   | 115.7 | 100.0% | 100.0% | Neurodegeneration due to cerebral folate transport deficiency, 613068  |
| FOXG1   | 162.5 | 99.7%  | 96.6%  | Rett syndrome, congenital variant, 613454  |
| FOXP1   | 117.6 | 100.0% | 99.9%  | Mental retardation with language impairment and with or without autistic features, 613670  |
| FOXP2   | 130.1 | 99.5%  | 98.4%  | Speech-language disorder-1, 602081   |
| FOXRED1 | 129.1 | 99.9%  | 99.0%  | Mitochondrial complex I deficiency, nuclear type 19, 618241  |
| FRAS1   | 123.1 | 99.9%  | 99.3%  | Fraser syndrome 1, 219000  |
| FRMD4A  | 124.0 | 91.5%  | 91.0%  | ?Corpus callosum, agenesis of, with facial anomalies and cerebellar ataxia, 616819   |
| FRMPD4  | 115.6 | 99.7%  | 97.7%  | Mental retardation, X-linked 104, 300983   |
| FRRS1L  | 100.0 | 89.3%  | 81.8%  | Epileptic encephalopathy, early infantile, 37, 616981  |
| FTCD    | 129.8 | 99.1%  | 96.1%  | Glutamate formiminotransferase deficiency, 229100  |
| FTO     | 99.1  | 83.8%  | 83.7%  | Growth retardation, developmental delay, facial dysmorphism, 612938  |
| FTSJ1   | 134.4 | 99.6%  | 96.5%  | Mental retardation, X-linked 9/44, 309549  |
| FUCA1   | 135.9 | 100.0% | 100.0% | Fucosidosis, 230000  |
| FUT8    | 130.4 | 100.0% | 99.4%  | Congenital disorder of glycosylation with defective fucosylation 1, 618005   |
| GABBR2  | 115.6 | 99.1%  | 95.6%  | Neurodevelopmental disorder with poor language and loss of hand skills, 617903<br>Epileptic encephalopathy, early infantile, 59, 617904  |
| GABRA1  | 164.8 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 19, 615744  |
| GABRA3  | 84.1  | 99.2%  | 95.7%  | No OMIM Disease ID   |
| GABRB1  | 174.8 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 45, 617153  |
| GABRB2  | 134.8 | 100.0% | 100.0% | Epileptic encephalopathy, infantile or early childhood, 2, 617829  |
| GABRB3  | 139.5 | 99.7%  | 98.5%  | Epileptic encephalopathy, early infantile, 43, 617113  |
| GABRG2  | 126.9 | 91.0%  | 90.0%  | Epileptic encephalopathy, early infantile, 74, 618396<br>Febrile seizures, familial, 8, 607681<br>Epilepsy, generalized, with febrile seizures plus, type 3, 607681                              |
| GAD1    | 114.6 | 100.0% | 99.8%  | ?Cerebral palsy, spastic quadriplegic, 1, 603513   |
| GALC    | 103.0 | 99.8%  | 98.1%  | Krabbe disease, 245200   |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| GALE    | 153.0 | 100.0% | 100.0% | Galactose epimerase deficiency, 230350  |
| GALT    | 165.3 | 100.0% | 100.0% | Galactosemia, 230400  |
| GAMT    | 125.7 | 99.7%  | 94.3%  | Cerebral creatine deficiency syndrome 2, 612736   |
| GATAD2B | 101.2 | 100.0% | 99.6%  | Mental retardation, autosomal dominant 18, 615074   |
| GATM    | 139.0 | 100.0% | 100.0% | Cerebral creatine deficiency syndrome 3, 612718   |
| GCH1    | 91.0  | 99.9%  | 99.4%  | Hyperphenylalaninemia, BH4-deficient, B, 233910<br>Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230   |
| GCSH    | 32.0  | 94.3%  | 74.1%  | ?Glycine encephalopathy, 605899   |
| GDI1    | 145.2 | 99.4%  | 97.9%  | Mental retardation, X-linked 41, 300849   |
| GFAP    | 111.6 | 91.9%  | 91.7%  | Alexander disease, 203450   |
| GFM1    | 104.4 | 100.0% | 98.9%  | Combined oxidative phosphorylation deficiency 1, 609060   |
| GFM2    | 117.8 | 99.0%  | 95.2%  | Combined oxidative phosphorylation deficiency 39, 618397  |
| GJA1    | 162.4 | 100.0% | 100.0% | Erythrokeratoderma variabilis et progressiva 3, 617525<br>Craniometaphyseal dysplasia, autosomal recessive, 218400<br>Atrioventricular septal defect 3, 600309<br>Oculodigital dysplasia, 164200<br>Syndactyly, type III, 186100<br>Oculodigital dysplasia, autosomal recessive, 257850<br>Hypoplastic left heart syndrome 1, 241550<br>Palmoplantar keratoderma with congenital alopecia, 104100 |
| GJB1    | 161.4 | 100.0% | 100.0% | Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800  |
| GJC2    | 59.7  | 97.7%  | 86.5%  | Spastic paraplegia 44, autosomal recessive, 613206<br>Lymphatic malformation 3, 613480<br>Leukodystrophy, hypomyelinating, 2, 608804  |
| GK      | 43.3  | 82.3%  | 61.8%  | Glycerol kinase deficiency, 307030  |
| GLB1    | 87.4  | 99.5%  | 95.2%  | GM1-gangliosidosis, type III, 230650<br>GM1-gangliosidosis, type I, 230500<br>Mucopolysaccharidosis type IVB (Morquio), 253010<br>GM1-gangliosidosis, type II, 230600   |
| GLDC    | 60.8  | 91.8%  | 80.4%  | Glycine encephalopathy, 605899  |
| GLI2    | 177.4 | 100.0% | 100.0% | Culler-Jones syndrome, 615849<br>Holoprosencephaly 9, 610829  |
| GLI3    | 151.8 | 100.0% | 99.5%  | Polydactyly, postaxial, types A1 and B, 174200<br>Greig cephalopolysyndactyly syndrome, 175700<br>Polydactyly, preaxial, type IV, 174700<br>Pallister-Hall syndrome, 146510   |
| GLIS3   | 133.1 | 100.0% | 99.6%  | Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199   |
| GLUD1   | 66.3  | 98.0%  | 88.9%  | Hyperinsulinism-hyperammonemia syndrome, 606762   |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| GLYCTK | 175.0 | 100.0% | 99.8%  | D-glyceric aciduria, 220120  |
| GM2A   | 129.1 | 100.0% | 100.0% | GM2-gangliosidosis, AB variant, 272750   |
| GMPPA  | 158.4 | 100.0% | 100.0% | Alacrima, achalasia, and mental retardation syndrome, 615510   |
| GMPPB  | 233.1 | 100.0% | 100.0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350<br>Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351<br>Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352   |
| GNAO1  | 160.9 | 93.8%  | 93.8%  | Epileptic encephalopathy, early infantile, 17, 615473<br>Neurodevelopmental disorder with involuntary movements, 617493  |
| GNAS   | 241.4 | 100.0% | 100.0% | ACTH-independent macronodular adrenal hyperplasia, 219080<br>Pseudohypoparathyroidism 1c, 612462<br>Pseudohypoparathyroidism 1b, 603233<br>Pseudopseudohypoparathyroidism, 612463<br>McCune-Albright syndrome, somatic, mosaic, 174800<br>Osseous heteroplasia, progressive, 166350<br>Pituitary adenoma 3, multiple types, somatic, 617686<br>Pseudohypoparathyroidism 1a, 103580 |
| GNB1   | 148.9 | 100.0% | 100.0% | Mental retardation, autosomal dominant 42, 616973<br>Leukemia, acute lymphoblastic, somatic, 613065  |
| GNB5   | 119.4 | 99.9%  | 98.0%  | Intellectual developmental disorder with cardiac arrhythmia, 617173<br>Language delay and ADHD/cognitive impairment with or without cardiac arrhythmia, 617182   |
| GNPAT  | 128.8 | 99.7%  | 96.6%  | Rhizomelic chondrodysplasia punctata, type 2, 222765   |
| GNPTAB | 149.5 | 100.0% | 99.4%  | Mucopolipidosis II alpha/beta, 252500<br>Mucopolipidosis III alpha/beta, 252600  |
| GNPTG  | 199.0 | 99.9%  | 99.4%  | Mucopolipidosis III gamma, 252605  |
| GNS    | 93.6  | 99.9%  | 97.2%  | Mucopolysaccharidosis type IIID, 252940  |
| GPAA1  | 137.4 | 99.9%  | 98.9%  | Glycosylphosphatidylinositol biosynthesis defect 15, 617810  |
| GPC3   | 76.8  | 98.9%  | 93.5%  | Simpson-Golabi-Behmel syndrome, type 1, 312870<br>Wilms tumor, somatic, 194070   |
| GPC4   | 107.1 | 99.9%  | 97.7%  | Keipert syndrome, 301026   |
| GPHN   | 147.8 | 99.8%  | 98.8%  | Molybdenum cofactor deficiency C, 615501   |
| GPSM2  | 121.0 | 100.0% | 99.4%  | Chudley-McCullough syndrome, 604213  |
| GPT2   | 130.4 | 100.0% | 99.6%  | Mental retardation, autosomal recessive 49, 616281   |
| GRIA3  | 83.0  | 98.9%  | 93.2%  | Mental retardation, X-linked 94, 300699  |
| GRIA4  | 123.6 | 99.6%  | 97.9%  | Neurodevelopmental disorder with or without seizures and gait abnormalities, 617864  |
| GRID2  | 148.3 | 100.0% | 99.6%  | Spinocerebellar ataxia, autosomal recessive 18, 616204   |
| GRIK2  | 121.6 | 96.2%  | 95.3%  | Mental retardation, autosomal recessive, 6, 611092   |

|        |       |        |        |   |
|--------|-------|--------|--------|---|
| GRIN1  | 186.6 | 100.0% | 100.0% | Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive, 617820<br>Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant, 614254 |
| GRIN2A | 139.8 | 100.0% | 100.0% | Epilepsy, focal, with speech disorder and with or without mental retardation, 245570  |
| GRIN2B | 168.9 | 99.9%  | 99.2%  | Epileptic encephalopathy, early infantile, 27, 616139<br>Mental retardation, autosomal dominant 6, 613970   |
| GRIN2D | 92.8  | 96.7%  | 85.3%  | Epileptic encephalopathy, early infantile, 46, 617162   |
| GRIP1  | 114.2 | 100.0% | 99.4%  | Fraser syndrome 3, 617667   |
| GRM1   | 167.3 | 100.0% | 100.0% | Spinocerebellar ataxia 44, 617691<br>Spinocerebellar ataxia, autosomal recessive 13, 614831   |
| GRN    | 193.7 | 100.0% | 100.0% | Ceroid lipofuscinosis, neuronal, 11, 614706<br>Aphasia, primary progressive, 607485<br>Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485   |
| GSE1   | 135.4 | 100.0% | 99.9%  | No OMIM Disease ID  |
| GSS    | 98.9  | 100.0% | 99.6%  | Glutathione synthetase deficiency, 266130<br>Hemolytic anemia due to glutathione synthetase deficiency, 231900  |
| GTF2H5 | 82.0  | 99.8%  | 97.4%  | Trichothiodystrophy 3, photosensitive, 616395   |
| GTPBP2 | 138.7 | 99.9%  | 99.2%  | Jaberi-Elahi syndrome, 617988   |
| GTPBP3 | 189.1 | 100.0% | 100.0% | Combined oxidative phosphorylation deficiency 23, 616198  |
| GUSB   | 106.6 | 92.6%  | 91.1%  | Mucopolysaccharidosis VII, 253220   |
| HACE1  | 135.7 | 100.0% | 99.4%  | Spastic paraplegia and psychomotor retardation with or without seizures, 616756   |
| HADH   | 118.2 | 99.3%  | 99.2%  | 3-hydroxyacyl-CoA dehydrogenase deficiency, 231530<br>Hyperinsulinemic hypoglycemia, familial, 4, 609975  |
| HADHA  | 74.6  | 96.1%  | 89.6%  | LCHAD deficiency, 609016<br>HELLP syndrome, maternal, of pregnancy, 609016<br>Fatty liver, acute, of pregnancy, 609016<br>Trifunctional protein deficiency, 609015  |
| HAX1   | 146.3 | 100.0% | 100.0% | Neutropenia, severe congenital 3, autosomal recessive, 610738   |
| HCCS   | 90.4  | 99.6%  | 96.6%  | Linear skin defects with multiple congenital anomalies 1, 309801  |
| HCFC1  | 114.5 | 99.5%  | 96.5%  | Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cbIX type ), 309541   |
| HCN1   | 144.1 | 100.0% | 99.9%  | Generalized epilepsy with febrile seizures plus, type 10, 618482<br>Epileptic encephalopathy, early infantile, 24, 615871   |
| HDAC4  | 131.1 | 100.0% | 100.0% | No OMIM Disease ID  |
| HDAC6  | 122.8 | 99.8%  | 98.0%  | ?Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia, 300863   |
| HDAC8  | 110.1 | 100.0% | 99.6%  | Cornelia de Lange syndrome 5, 300882  |
| HECW2  | 112.4 | 99.9%  | 98.8%  | Neurodevelopmental disorder with hypotonia, seizures, and absent language, 617268   |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| HEPACAM  | 127.8 | 95.0%  | 89.6%  | Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925<br>Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926   |
| HERC1    | 145.0 | 100.0% | 99.7%  | Macrocephaly, dysmorphic facies, and psychomotor retardation, 617011  |
| HERC2    | 99.7  | 80.6%  | 76.7%  | Mental retardation, autosomal recessive 38, 615516  |
| HESX1    | 65.7  | 99.9%  | 97.5%  | Pituitary hormone deficiency, combined, 5, 182230<br>Septooptic dysplasia, 182230<br>Growth hormone deficiency with pituitary anomalies, 182230   |
| HEXA     | 112.3 | 93.8%  | 92.6%  | GM2-gangliosidosis, several forms, 272800<br>Tay-Sachs disease, 272800  |
| HEXB     | 173.2 | 99.8%  | 97.3%  | Sandhoff disease, infantile, juvenile, and adult forms, 268800  |
| HGSNAT   | 99.9  | 88.2%  | 86.3%  | Retinitis pigmentosa 73, 616544<br>Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930   |
| HIBCH    | 69.7  | 95.5%  | 75.9%  | 3-hydroxyisobutryl-CoA hydrolase deficiency, 250620   |
| HIST1H1E | 125.1 | 100.0% | 100.0% | Rahman syndrome, 617537   |
| HIST1H4C | 109.9 | 100.0% | 100.0% | No OMIM Disease ID  |
| HIVEP2   | 171.1 | 100.0% | 100.0% | Mental retardation, autosomal dominant 43, 616977   |
| HLCS     | 148.0 | 100.0% | 100.0% | Holocarboxylase synthetase deficiency, 253270   |
| HMGCL    | 124.9 | 100.0% | 99.5%  | HMG-CoA lyase deficiency, 246450  |
| HNMT     | 132.7 | 100.0% | 99.7%  | Mental retardation, autosomal recessive 51, 616739  |
| HNRNPH2  | 131.4 | 100.0% | 100.0% | Mental retardation, X-linked, syndromic, Bain type, 300986  |
| HNRNPK   | 61.0  | 87.9%  | 78.3%  | Au-Kline syndrome, 616580   |
| HNRNPU   | 154.7 | 100.0% | 99.3%  | Epileptic encephalopathy, early infantile, 54, 617391   |
| HOXA1    | 184.7 | 100.0% | 100.0% | Athabaskan brainstem dysgenesis syndrome, 601536<br>Bosley-Salih-Alorainy syndrome, 601536  |
| HPD      | 159.7 | 100.0% | 99.9%  | Tyrosinemia, type III, 276710<br>Hawkinsinuria, 140350  |
| HPRT1    | 56.9  | 97.8%  | 87.8%  | HPRT-related gout, 300323<br>Lesch-Nyhan syndrome, 300322   |
| HRAS     | 196.0 | 100.0% | 100.0% | Nevus sebaceous or woolly hair nevus, somatic, 162900<br>Congenital myopathy with excess of muscle spindles, 218040<br>Bladder cancer, somatic, 109800<br>Thyroid carcinoma, follicular, somatic, 188470<br>Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200<br>Spitz nevus or nevus spilus, somatic, 137550<br>Costello syndrome, 218040 |
| HSD17B10 | 98.0  | 100.0% | 99.5%  | HSD10 mitochondrial disease, 300438   |

|          |       |        |        |  |
|----------|-------|--------|--------|--|
| HSD17B4  | 106.4 | 95.5%  | 93.1%  | D-bifunctional protein deficiency, 261515<br>Perrault syndrome 1, 233400   |
| HSPA9    | 83.8  | 88.2%  | 84.2%  | Even-plus syndrome, 616854<br>Anemia, sideroblastic, 4, 182170   |
| HSPD1    | 73.7  | 97.9%  | 92.1%  | Spastic paraplegia 13, autosomal dominant, 605280<br>Leukodystrophy, hypomyelinating, 4, 612233  |
| HTRA2    | 145.3 | 100.0% | 99.7%  | 3-methylglutaconic aciduria, type VIII, 617248   |
| HUWE1    | 82.1  | 99.1%  | 95.0%  | Mental retardation, X-linked syndromic, Turner type, 309590  |
| HYLS1    | 160.4 | 100.0% | 100.0% | Hydrolethalus syndrome, 236680   |
| IARS     | 124.2 | 99.9%  | 99.2%  | Growth retardation, impaired intellectual development, hypotonia, and hepatopathy, 617093  |
| IARS2    | 145.7 | 100.0% | 100.0% | ?Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia, 616007  |
| IDS      | 105.1 | 99.8%  | 97.2%  | Mucopolysaccharidosis II, 309900   |
| IDUA     | 169.2 | 99.3%  | 96.4%  | Mucopolysaccharidosis Ih/s, 607015<br>Mucopolysaccharidosis Ih, 607014<br>Mucopolysaccharidosis Is, 607016   |
| IER3IP1  | 108.7 | 88.3%  | 80.0%  | Microcephaly, epilepsy, and diabetes syndrome, 614231  |
| IFIH1    | 110.9 | 99.8%  | 98.2%  | Aicardi-Goutieres syndrome 7, 615846<br>Singleton-Merten syndrome 1, 182250  |
| IFT172   | 98.4  | 100.0% | 99.5%  | Retinitis pigmentosa 71, 616394<br>Short-rib thoracic dysplasia 10 with or without polydactyly, 615630   |
| IFT81    | 90.5  | 93.0%  | 88.0%  | Short-rib thoracic dysplasia 19 with or without polydactyly, 617895  |
| IGBP1    | 106.4 | 98.8%  | 93.9%  | Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472  |
| IGF1     | 100.6 | 100.0% | 100.0% | Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747   |
| IGF1R    | 123.1 | 100.0% | 99.7%  | Insulin-like growth factor I, resistance to, 270450  |
| IKBKG    | 64.7  | 90.1%  | 80.2%  | Immunodeficiency 33, 300636<br>Incontinentia pigmenti, 308300<br>Immunodeficiency, isolated, 300584<br>Ectodermal dysplasia and immunodeficiency 1, 300291<br>Invasive pneumococcal disease, recurrent isolated, 2, 300640<br>Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 |
| IL1RAPL1 | 100.0 | 99.5%  | 97.6%  | Mental retardation, X-linked 21/34, 300143   |
| IMPA1    | 73.2  | 96.0%  | 84.6%  | Mental retardation, autosomal recessive 59, 617323   |
| INPP5E   | 131.1 | 100.0% | 99.3%  | Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156<br>Joubert syndrome 1, 213300   |
| INPP5K   | 94.7  | 100.0% | 99.5%  | Muscular dystrophy, congenital, with cataracts and intellectual disability, 617404   |
| IQSEC2   | 81.5  | 96.6%  | 90.5%  | Mental retardation, X-linked 1/78, 309530  |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| IRF2BPL | 197.8 | 99.6%  | 97.8%  | Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, 618088  |
| ISCA2   | 112.2 | 99.8%  | 97.4%  | Multiple mitochondrial dysfunctions syndrome 4, 616370   |
| ISPD    | 112.0 | 99.7%  | 97.8%  | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643   |
| ITGA7   | 142.3 | 99.8%  | 98.4%  | Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204  |
| ITPA    | 142.5 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 35, 616647  |
| ITPR1   | 136.4 | 100.0% | 99.8%  | Spinocerebellar ataxia 29, congenital nonprogressive, 117360<br>Spinocerebellar ataxia 15, 606658<br>Gillespie syndrome, 206700  |
| IVD     | 106.7 | 100.0% | 100.0% | Isovaleric acidemia, 243500  |
| JAG1    | 143.4 | 99.4%  | 97.6%  | Alagille syndrome 1, 118450<br>Tetralogy of Fallot, 187500<br>?Deafness, congenital heart defects, and posterior embryotoxon, 617992   |
| JAM3    | 132.0 | 100.0% | 100.0% | Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730  |
| JMJD1C  | 136.5 | 99.9%  | 99.5%  | No OMIM Disease ID   |
| KANK1   | 129.0 | 100.0% | 99.7%  | Cerebral palsy, spastic quadriplegic, 2, 612900  |
| KANSL1  | 156.7 | 99.8%  | 99.1%  | Koolen-De Vries syndrome, 610443   |
| KAT6A   | 155.1 | 100.0% | 99.9%  | Mental retardation, autosomal dominant 32, 616268  |
| KAT6B   | 162.3 | 99.8%  | 99.2%  | SBBYSS syndrome, 603736<br>Genitopatellar syndrome, 606170   |
| KATNB1  | 170.5 | 100.0% | 100.0% | Lissencephaly 6, with microcephaly, 616212   |
| KCNA2   | 132.6 | 100.0% | 99.4%  | Epileptic encephalopathy, early infantile, 32, 616366  |
| KCNA4   | 128.0 | 100.0% | 100.0% | Microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum, 618284  |
| KCNB1   | 141.6 | 100.0% | 99.8%  | Epileptic encephalopathy, early infantile, 26, 616056  |
| KCNC1   | 189.4 | 100.0% | 100.0% | Epilepsy, progressive myoclonic 7, 616187  |
| KCNC3   | 126.1 | 94.7%  | 80.0%  | Spinocerebellar ataxia 13, 605259  |
| KCNH1   | 159.4 | 98.7%  | 98.4%  | Temple-Baraitser syndrome, 611816<br>Zimmermann-Laband syndrome 1, 135500  |
| KCNJ10  | 157.5 | 89.3%  | 88.6%  | Enlarged vestibular aqueduct, digenic, 600791<br>SESAME syndrome, 612780   |
| KCNJ11  | 222.1 | 100.0% | 100.0% | Maturity-onset diabetes of the young, type 13, 616329<br>Diabetes, permanent neonatal, with or without neurologic features, 606176<br>Diabetes mellitus, transient neonatal, 3, 610582<br>Hyperinsulinemic hypoglycemia, familial, 2, 601820 |
| KCNJ6   | 165.7 | 100.0% | 100.0% | Keppen-Lubinsky syndrome, 614098   |
| KCNK4   | 221.2 | 100.0% | 100.0% | Facial dysmorphism, hypertrichosis, epilepsy, intellectual/developmental delay, and gingival overgrowth syndrome, 618381   |



|           |       |        |        |  |
|-----------|-------|--------|--------|--|
| KCNK9     | 189.3 | 100.0% | 100.0% | Birk-Barel mental retardation dysmorphism syndrome, 612292   |
| KCNQ2     | 133.0 | 91.5%  | 90.4%  | Epileptic encephalopathy, early infantile, 7, 613720<br>Seizures, benign neonatal, 1, 121200<br>Myokymia, 121200   |
| KCNQ3     | 116.5 | 100.0% | 98.7%  | Seizures, benign neonatal, 2, 121201   |
| KCNQ5     | 140.1 | 99.7%  | 98.5%  | Mental retardation, autosomal dominant 46, 617601  |
| KCNT1     | 145.3 | 96.3%  | 95.2%  | Epilepsy, nocturnal frontal lobe, 5, 615005<br>Epileptic encephalopathy, early infantile, 14, 614959   |
| KCTD7     | 171.1 | 95.0%  | 95.0%  | Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726  |
| KDM1A     | 134.2 | 100.0% | 99.4%  | Cleft palate, psychomotor retardation, and distinctive facial features, 616728   |
| KDM3B     | 124.1 | 99.7%  | 97.9%  | No OMIM Disease ID   |
| KDM5B     | 123.2 | 99.1%  | 97.2%  | Mental retardation, autosomal recessive 65, 618109   |
| KDM5C     | 111.1 | 99.6%  | 97.5%  | Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534   |
| KDM6A     | 98.1  | 95.6%  | 87.7%  | Kabuki syndrome 2, 300867  |
| KDM6B     | 160.4 | 99.9%  | 98.1%  | Neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, 618505  |
| KIAA0586  | 115.1 | 97.3%  | 92.6%  | Joubert syndrome 23, 616490<br>Short-rib thoracic dysplasia 14 with polydactyly, 616546  |
| KIAA1109  | 137.8 | 99.8%  | 98.9%  | Alkuraya-Kucinkas syndrome, 617822   |
| KIDINS220 | 138.5 | 100.0% | 99.9%  | Spastic paraplegia, intellectual disability, nystagmus, and obesity, 617296  |
| KIF11     | 89.7  | 97.6%  | 94.9%  | Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950  |
| KIF14     | 112.4 | 99.8%  | 97.7%  | ?Meckel syndrome 12, 616258<br>Microcephaly 20, primary, autosomal recessive, 617914   |
| KIF1A     | 125.3 | 99.8%  | 98.2%  | Neuropathy, hereditary sensory, type IIC, 614213<br>Mental retardation, autosomal dominant 9, 614255<br>Spastic paraplegia 30, autosomal recessive, 610357 |
| KIF1BP    | 168.4 | 96.1%  | 96.1%  | Goldberg-Shprintzen megacolon syndrome, 609460   |
| KIF2A     | 103.8 | 99.5%  | 95.9%  | Cortical dysplasia, complex, with other brain malformations 3, 615411  |
| KIF4A     | 78.5  | 98.5%  | 93.1%  | ?Mental retardation, X-linked 100, 300923  |
| KIF5C     | 113.8 | 100.0% | 99.0%  | Cortical dysplasia, complex, with other brain malformations 2, 615282  |
| KIF7      | 120.4 | 99.3%  | 96.6%  | ?Hydroletharus syndrome 2, 614120<br>Acrocallosal syndrome, 200990<br>Joubert syndrome 12, 200990<br>?Al-Gazali-Bakalinova syndrome, 607131                |
| KIRREL3   | 138.0 | 99.9%  | 99.4%  | No OMIM Disease ID   |
| KLF7      | 131.4 | 100.0% | 100.0% | No OMIM Disease ID   |
| KLHL15    | 143.1 | 100.0% | 99.9%  | Mental retardation, X-linked 103, 300982   |
| KMT2A     | 138.5 | 100.0% | 99.9%  | Wiedemann-Steiner syndrome, 605130   |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| KMT2B  | 156.7 | 98.1%  | 94.7%  | Dystonia 28, childhood-onset, 617284   |
| KMT2C  | 142.7 | 91.8%  | 90.3%  | Kleefstra syndrome 2, 617768   |
| KMT2D  | 150.7 | 100.0% | 99.9%  | Kabuki syndrome 1, 147920  |
| KMT2E  | 156.1 | 99.9%  | 98.4%  | O'Donnell-Luria-Rodan syndrome, 618512   |
| KMT5B  | 170.8 | 100.0% | 99.9%  | Mental retardation, autosomal dominant 51, 617788  |
| KNL1   | 103.6 | 99.0%  | 97.3%  | Microcephaly 4, primary, autosomal recessive, 604321   |
| KPTN   | 163.9 | 100.0% | 100.0% | Mental retardation, autosomal recessive 41, 615637   |
| KRAS   | 64.0  | 99.8%  | 96.8%  | Leukemia, acute myeloid, 601626<br>Oculoectodermal syndrome, somatic, 600268<br>Breast cancer, somatic, 114480<br>RAS-associated autoimmune leukoproliferative disorder, 614470<br>Cardiofaciocutaneous syndrome 2, 615278<br>Arteriovenous malformation of the brain, somatic, 108010<br>Bladder cancer, somatic, 109800<br>Pancreatic carcinoma, somatic, 260350<br>Lung cancer, somatic, 211980<br>Gastric cancer, somatic, 137215<br>Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200<br>Noonan syndrome 3, 609942 |
| L1CAM  | 138.3 | 99.9%  | 98.6%  | MASA syndrome, 303350<br>Hydrocephalus with Hirschsprung disease, 307000<br>Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000<br>Corpus callosum, partial agenesis of, 304100<br>CRASH syndrome, 303350<br>Hydrocephalus due to aqueductal stenosis, 307000  |
| L2HGDH | 123.6 | 99.2%  | 97.2%  | L-2-hydroxyglutaric aciduria, 236792   |
| LAMA1  | 119.9 | 100.0% | 99.6%  | Poretti-Boltshauser syndrome, 615960   |
| LAMA2  | 131.6 | 100.0% | 99.4%  | Muscular dystrophy, limb-girdle, autosomal recessive 23, 618138<br>Muscular dystrophy, congenital, merosin deficient or partially deficient, 607855  |
| LAMB1  | 147.7 | 100.0% | 99.7%  | Lissencephaly 5, 615191  |
| LAMC3  | 163.5 | 99.9%  | 99.2%  | Cortical malformations, occipital, 614115  |
| LAMP2  | 89.8  | 97.8%  | 92.3%  | Danon disease, 300257  |
| LARGE1 | 122.8 | 100.0% | 99.8%  | Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154  |
| LARP7  | 74.1  | 89.4%  | 74.5%  | Alazami syndrome, 615071   |
| LAS1L  | 83.2  | 99.5%  | 96.4%  | Wilson-Turner syndrome, 309585   |
| LIAS   | 124.4 | 100.0% | 98.7%  | Hyperglycinemia, lactic acidosis, and seizures, 614462   |
| LIG4   | 170.5 | 100.0% | 99.9%  | LIG4 syndrome, 606593  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| LINGO1   | 231.7 | 100.0% | 100.0% | Mental retardation, autosomal recessive 64, 618103  |
| LINS1    | 135.6 | 100.0% | 99.5%  | Mental retardation, autosomal recessive 27, 614340  |
| LMAN2L   | 113.2 | 100.0% | 99.4%  | ?Mental retardation, autosomal recessive, 52, 616887  |
| LONP1    | 164.8 | 100.0% | 100.0% | CODAS syndrome, 600373  |
| LRP2     | 140.5 | 100.0% | 99.9%  | Donnai-Barrow syndrome, 222448  |
| LRPPRC   | 126.3 | 100.0% | 99.7%  | Leigh syndrome, French-Canadian type, 220111  |
| LYST     | 135.6 | 99.3%  | 97.1%  | Chediak-Higashi syndrome, 214500  |
| LZTFL1   | 116.5 | 99.9%  | 99.2%  | Bardet-Biedl syndrome 17, 615994  |
| LZTR1    | 157.2 | 100.0% | 99.9%  | Noonan syndrome 2, 605275<br>Noonan syndrome 10, 616564   |
| MAB21L1  | 187.7 | 100.0% | 100.0% | Cerebellar, ocular, craniofacial, and genital syndrome, 618479  |
| MAB21L2  | 265.2 | 100.0% | 100.0% | Microphthalmia/coloboma and skeletal dysplasia syndrome, 615877   |
| MACF1    | 133.2 | 100.0% | 99.5%  | Lissencephaly 9 with complex brainstem malformation, 618325   |
| MAF      | 103.8 | 89.3%  | 84.7%  | Ayme-Gripp syndrome, 601088<br>Cataract 21, multiple types, 610202  |
| MAG      | 175.3 | 100.0% | 99.9%  | Spastic paraplegia 75, autosomal recessive, 616680  |
| MAGEL2   | 137.7 | 98.8%  | 94.4%  | Schaaf-Yang syndrome, 615547  |
| MAN1B1   | 137.5 | 100.0% | 99.9%  | Mental retardation, autosomal recessive 15, 614202  |
| MAN2B1   | 139.1 | 99.9%  | 99.1%  | Mannosidosis, alpha-, types I and II, 248500  |
| MANBA    | 117.1 | 99.7%  | 98.1%  | Mannosidosis, beta, 248510  |
| MAOA     | 100.1 | 100.0% | 99.2%  | Brunner syndrome, 300615  |
| MAP1B    | 131.5 | 99.9%  | 99.6%  | No OMIM Disease ID  |
| MAP2K1   | 96.7  | 99.6%  | 97.1%  | Cardiofaciocutaneous syndrome 3, 615279   |
| MAP2K2   | 139.8 | 99.3%  | 95.6%  | Cardiofaciocutaneous syndrome 4, 615280   |
| MAPK8IP3 | 181.0 | 100.0% | 100.0% | Neurodevelopmental disorder with or without variable brain abnormalities, 618443  |
| MAPRE2   | 163.4 | 99.8%  | 98.4%  | Symmetric circumferential skin creases, congenital, 2, 616734   |
| MASP1    | 140.7 | 100.0% | 99.5%  | 3MC syndrome 1, 257920  |
| MAST1    | 187.1 | 100.0% | 99.9%  | Mega-corpus-callosum syndrome with cerebellar hypoplasia and cortical malformations, 618273   |
| MAT1A    | 154.2 | 99.7%  | 98.2%  | Methionine adenosyltransferase deficiency, autosomal recessive, 250850<br>Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850                |
| MBD5     | 151.8 | 99.9%  | 99.8%  | Mental retardation, autosomal dominant 1, 156200  |
| MBOAT7   | 121.9 | 100.0% | 99.9%  | Mental retardation, autosomal recessive 57, 617188  |
| MBTPS2   | 109.0 | 99.9%  | 98.4%  | Osteogenesis imperfecta, type XIX, 301014<br>?Olmsted syndrome, X-linked, 300918<br>IFAP syndrome with or without BRESHECK syndrome, 308205<br>Keratosis follicularis spinulosa decalvans, X-linked, 308800 |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| MCCC1   | 138.0 | 100.0% | 99.6%  | 3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200   |
| MCCC2   | 121.8 | 100.0% | 99.9%  | 3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210   |
| MCOLN1  | 170.5 | 100.0% | 99.4%  | Mucopolipidosis IV, 252650  |
| MCPH1   | 138.1 | 100.0% | 98.7%  | Microcephaly 1, primary, autosomal recessive, 251200  |
| MDH2    | 116.5 | 98.0%  | 98.0%  | Epileptic encephalopathy, early infantile, 51, 617339   |
| MECP2   | 135.2 | 100.0% | 99.5%  | Mental retardation, X-linked syndromic, Lubs type, 300260<br>Encephalopathy, neonatal severe, 300673<br>Mental retardation, X-linked, syndromic 13, 300055<br>Rett syndrome, atypical, 312750<br>Rett syndrome, 312750<br>Rett syndrome, preserved speech variant, 312750 |
| MECR    | 114.2 | 100.0% | 99.7%  | Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities, 617282   |
| MED12   | 89.4  | 99.6%  | 96.5%  | Ohdo syndrome, X-linked, 300895<br>Lujan-Fryns syndrome, 309520<br>Opitz-Kaveggia syndrome, 305450  |
| MED13   | 146.3 | 100.0% | 99.7%  | No OMIM Disease ID  |
| MED13L  | 112.2 | 100.0% | 99.8%  | Transposition of the great arteries, dextro-looped 1, 608808<br>Mental retardation and distinctive facial features with or without cardiac defects, 616789  |
| MED17   | 134.7 | 97.8%  | 94.7%  | Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668  |
| MED23   | 131.6 | 99.7%  | 98.5%  | Mental retardation, autosomal recessive 18, 614249  |
| MED25   | 148.0 | 100.0% | 99.9%  | ?Charcot-Marie-Tooth disease, type 2B2, 605589<br>Basel-Vanagait-Smirin-Yosef syndrome, 616449  |
| MEF2C   | 131.2 | 99.5%  | 95.7%  | Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443  |
| MEGF8   | 158.7 | 100.0% | 99.8%  | Carpenter syndrome 2, 614976  |
| MEIS2   | 128.4 | 100.0% | 99.9%  | Cleft palate, cardiac defects, and mental retardation, 600987   |
| METTL23 | 117.0 | 100.0% | 100.0% | Mental retardation, autosomal recessive 44, 615942  |
| METTL5  | 107.2 | 99.3%  | 97.0%  | Intellectual developmental disorder, autosomal recessive 72, 618665   |
| MFF     | 86.8  | 93.5%  | 88.5%  | Encephalopathy due to defective mitochondrial and peroxisomal fission 2, 617086   |
| MFSD2A  | 121.3 | 100.0% | 99.6%  | Microcephaly 15, primary, autosomal recessive, 616486   |
| MFSD8   | 117.4 | 100.0% | 99.6%  | Macular dystrophy with central cone involvement, 616170<br>Ceroid lipofuscinosis, neuronal, 7, 610951   |
| MGAT2   | 155.6 | 100.0% | 100.0% | Congenital disorder of glycosylation, type IIa, 212066  |
| MGP     | 134.2 | 98.6%  | 93.2%  | Keutel syndrome, 245150   |
| MICU1   | 103.4 | 98.7%  | 96.2%  | Myopathy with extrapyramidal signs, 615673  |
| MID1    | 131.5 | 99.9%  | 98.4%  | Opitz GBBB syndrome, type I, 300000   |
| MID2    | 111.8 | 99.7%  | 98.0%  | ?Mental retardation, X-linked 101, 300928   |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| MKKS   | 161.5 | 83.2%  | 83.2%  | Bardet-Biedl syndrome 6, 605231<br>McKusick-Kaufman syndrome, 236700   |
| MKS1   | 98.8  | 99.9%  | 98.5%  | Bardet-Biedl syndrome 13, 615990<br>Joubert syndrome 28, 617121<br>Meckel syndrome 1, 249000   |
| MLC1   | 102.4 | 100.0% | 99.9%  | Megalencephalic leukoencephalopathy with subcortical cysts, 604004   |
| MLYCD  | 105.5 | 99.7%  | 97.3%  | Malonyl-CoA decarboxylase deficiency, 248360   |
| MMAA   | 168.7 | 100.0% | 100.0% | Methylmalonic aciduria, vitamin B12-responsive, 251100   |
| MMAB   | 101.3 | 100.0% | 100.0% | Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110                                   |
| MMACHC | 214.4 | 100.0% | 100.0% | Methylmalonic aciduria and homocystinuria, cblC type, 277400   |
| MMADHC | 76.8  | 93.0%  | 77.2%  | Homocystinuria, cblD type, variant 1, 277410<br>Methylmalonic aciduria and homocystinuria, cblD type, 277410<br>Methylmalonic aciduria, cblD type, variant 2, 277410 |
| MOCS1  | 101.3 | 99.3%  | 96.6%  | Molybdenum cofactor deficiency A, 252150   |
| MOCS2  | 134.2 | 99.6%  | 99.6%  | Molybdenum cofactor deficiency B, 252160   |
| MOGS   | 157.9 | 100.0% | 100.0% | Congenital disorder of glycosylation, type IIb, 606056   |
| MPDU1  | 110.1 | 100.0% | 99.8%  | Congenital disorder of glycosylation, type If, 609180  |
| MPDZ   | 127.3 | 99.6%  | 98.1%  | Hydrocephalus, congenital, 2, with or without brain or eye anomalies, 615219   |
| MPLKIP | 106.6 | 100.0% | 99.9%  | Trichothiodystrophy 4, nonphotosensitive, 234050   |
| MRPS22 | 138.5 | 100.0% | 97.3%  | Combined oxidative phosphorylation deficiency 5, 611719<br>Ovarian dysgenesis 7, 618117  |
| MSL3   | 77.3  | 95.2%  | 84.1%  | Mental retardation, X-linked, syndromic, 36, 301032  |
| MSMO1  | 47.0  | 96.2%  | 87.7%  | Microcephaly, congenital cataract, and psoriasiform dermatitis, 616834   |
| MTFMT  | 131.5 | 100.0% | 99.7%  | Combined oxidative phosphorylation deficiency 15, 614947<br>Mitochondrial complex I deficiency, nuclear type 27, 618248  |
| MTHFR  | 124.2 | 98.5%  | 96.7%  | Homocystinuria due to MTHFR deficiency, 236250   |
| MTOR   | 116.6 | 100.0% | 99.2%  | Smith-Kingsmore syndrome, 616638<br>Focal cortical dysplasia, type II, somatic, 607341   |
| MTR    | 134.7 | 100.0% | 99.6%  | Homocystinuria-megaloblastic anemia, cblG complementation type, 250940   |
| MTRR   | 135.6 | 100.0% | 99.2%  | Homocystinuria-megaloblastic anemia, cbl E type, 236270  |
| MUT    | 128.8 | 100.0% | 99.0%  | Methylmalonic aciduria, mut(0) type, 251000  |
| MVK    | 130.3 | 90.5%  | 90.4%  | Hyper-IgD syndrome, 260920<br>Porokeratosis 3, multiple types, 175900<br>Mevalonic aciduria, 610377  |
| MYCN   | 200.6 | 100.0% | 100.0% | Feingold syndrome 1, 164280  |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| MYH9    | 140.9 | 99.7%  | 99.0%  | Deafness, autosomal dominant 17, 603622<br>Macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss, 155100                         |
| MYO5A   | 109.9 | 99.7%  | 98.5%  | Griscelli syndrome, type 1, 214450  |
| MYT1L   | 154.1 | 100.0% | 99.9%  | Mental retardation, autosomal dominant 39, 616521   |
| NAA10   | 112.8 | 100.0% | 99.4%  | Ogden syndrome, 300855<br>?Microphthalmia, syndromic 1, 309800  |
| NAA15   | 92.0  | 97.6%  | 94.4%  | Mental retardation, autosomal dominant 50, 617787   |
| NACC1   | 188.0 | 100.0% | 100.0% | Neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, 617393   |
| NAGA    | 131.4 | 100.0% | 100.0% | Kanzaki disease, 609242<br>Schindler disease, type I, 609241<br>Schindler disease, type III, 609241   |
| NAGLU   | 130.5 | 98.5%  | 95.6%  | Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920<br>?Charcot-Marie-Tooth disease, axonal, type 2V, 616491   |
| NALCN   | 117.7 | 99.7%  | 98.5%  | Hypotonia, infantile, with psychomotor retardation and characteristic facies 1, 615419<br>Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 |
| NANS    | 105.0 | 100.0% | 99.3%  | Spondyloepimetaphyseal dysplasia, Camera-Genevieve type, 610442   |
| NARS2   | 121.5 | 97.6%  | 97.4%  | ?Deafness, autosomal recessive 94, 618434<br>Combined oxidative phosphorylation deficiency 24, 616239   |
| NAXE    | 90.7  | 99.8%  | 97.2%  | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 617186   |
| NBEA    | 121.3 | 91.9%  | 90.4%  | No OMIM Disease ID  |
| NBN     | 90.6  | 100.0% | 98.2%  | Nijmegen breakage syndrome, 251260<br>Aplastic anemia, 609135<br>Leukemia, acute lymphoblastic, 613065  |
| NDE1    | 95.8  | 100.0% | 99.8%  | Lissencephaly 4 (with microcephaly), 614019<br>?Microhydranencephaly, 605013  |
| NDP     | 96.2  | 100.0% | 99.6%  | Exudative vitreoretinopathy 2, X-linked, 305390<br>Norrie disease, 310600   |
| NDST1   | 204.8 | 100.0% | 100.0% | Mental retardation, autosomal recessive 46, 616116  |
| NDUFA1  | 195.4 | 99.9%  | 98.7%  | Mitochondrial complex I deficiency, nuclear type 12, 301020   |
| NDUFA11 | 129.7 | 100.0% | 98.5%  | Mitochondrial complex I deficiency, nuclear type 14, 618236   |
| NDUFA12 | 162.1 | 100.0% | 99.9%  | ?Mitochondrial complex I deficiency, nuclear type 23, 618244  |
| NDUFA2  | 179.9 | 100.0% | 100.0% | ?Mitochondrial complex I deficiency, nuclear type 13, 618235  |
| NDUFAF3 | 159.3 | 100.0% | 99.9%  | Mitochondrial complex I deficiency, nuclear type 18, 618240   |
| NDUFAF5 | 128.0 | 99.8%  | 99.3%  | Mitochondrial complex I deficiency, nuclear type 16, 618238   |
| NDUFS1  | 140.7 | 100.0% | 99.7%  | Mitochondrial complex I deficiency, nuclear type 5, 618226  |
| NDUFS2  | 102.9 | 100.0% | 99.9%  | Mitochondrial complex I deficiency, nuclear type 6, 618228  |
| NDUFS3  | 132.3 | 90.7%  | 90.6%  | Mitochondrial complex I deficiency, nuclear type 8, 618230  |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| NDUFS4 | 148.6 | 100.0% | 99.6%  | Mitochondrial complex I deficiency, nuclear type 1, 252010   |
| NDUFS6 | 120.0 | 100.0% | 100.0% | Mitochondrial complex I deficiency, nuclear type 9, 618232   |
| NDUFS7 | 157.0 | 100.0% | 100.0% | Mitochondrial complex I deficiency, nuclear type 3, 618224   |
| NDUFS8 | 171.3 | 100.0% | 100.0% | Mitochondrial complex I deficiency, nuclear type 2, 618222   |
| NDUFV1 | 154.4 | 100.0% | 99.5%  | Mitochondrial complex I deficiency, nuclear type 4, 618225   |
| NDUFV2 | 71.5  | 91.8%  | 77.9%  | Mitochondrial complex I deficiency, nuclear type 7, 618229   |
| NEDD4L | 96.3  | 72.4%  | 71.5%  | Periventricular nodular heterotopia 7, 617201  |
| NEU1   | 150.1 | 99.5%  | 96.5%  | Sialidosis, type II, 256550<br>Sialidosis, type I, 256550  |
| NEXMIF | 135.1 | 99.9%  | 99.4%  | Mental retardation, X-linked 98, 300912  |
| NF1    | 105.8 | 92.5%  | 89.3%  | Watson syndrome, 193520<br>Neurofibromatosis, type 1, 162200<br>Neurofibromatosis-Noonan syndrome, 601321<br>Leukemia, juvenile myelomonocytic, 607785<br>Neurofibromatosis, familial spinal, 162210 |
| NFIA   | 158.0 | 99.9%  | 99.0%  | Brain malformations with or without urinary tract defects, 613735  |
| NFIB   | 109.8 | 97.5%  | 96.8%  | Macrocephaly, acquired, with impaired intellectual development, 618286   |
| NFIX   | 195.4 | 100.0% | 99.8%  | Marshall-Smith syndrome, 602535<br>Sotos syndrome 2, 614753  |
| NFU1   | 61.6  | 96.2%  | 77.8%  | Multiple mitochondrial dysfunctions syndrome 1, 605711   |
| NGLY1  | 134.1 | 100.0% | 99.9%  | Congenital disorder of deglycosylation, 615273   |
| NHS    | 114.3 | 98.6%  | 96.5%  | Nance-Horan syndrome, 302350<br>Cataract 40, X-linked, 302200  |
| NIPBL  | 123.0 | 98.9%  | 96.7%  | Cornelia de Lange syndrome 1, 122470   |
| NKX2-1 | 102.8 | 100.0% | 99.9%  | Chorea, hereditary benign, 118700<br>Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978  |
| NLGN3  | 129.8 | 100.0% | 99.2%  | No OMIM disease ID   |
| NLGN4X | 154.6 | 99.5%  | 97.8%  | Mental retardation, X-linked, 300495   |
| NONO   | 83.1  | 99.7%  | 96.8%  | Mental retardation, X-linked, syndromic 34, 300967   |
| NPC1   | 120.3 | 100.0% | 99.4%  | Niemann-Pick disease, type D, 257220<br>Niemann-Pick disease, type C1, 257220  |
| NPC2   | 130.7 | 100.0% | 99.9%  | Niemann-pick disease, type C2, 607625  |
| NPHP1  | 119.7 | 99.8%  | 97.8%  | Nephronophthisis 1, juvenile, 256100<br>Senior-Loken syndrome-1, 266900<br>Joubert syndrome 4, 609583  |
| NR2F1  | 261.9 | 100.0% | 100.0% | Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722   |
| NR4A2  | 153.2 | 100.0% | 100.0% | No OMIM Disease ID   |

|       |       |        |        |  |
|-------|-------|--------|--------|--|
| NRAS  | 145.3 | 100.0% | 100.0% | Epidermal nevus, somatic, 162900<br>Melanocytic nevus syndrome, congenital, somatic, 137550<br>Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaicism, 163200<br>Colorectal cancer, somatic, 114500<br>?RAS-associated autoimmune lymphoproliferative syndrome type IV, somatic, 614470<br>Thyroid carcinoma, follicular, somatic, 188470<br>Neurocutaneous melanosis, somatic, 249400<br>Noonan syndrome 6, 613224 |
| NRXN1 | 147.9 | 97.6%  | 97.3%  | Pitt-Hopkins-like syndrome 2, 614325   |
| NSD1  | 152.6 | 100.0% | 99.8%  | Sotos syndrome 1, 117550   |
| NSD2  | 135.1 | 99.9%  | 98.3%  | No OMIM Disease ID   |
| NSDHL | 133.7 | 99.9%  | 98.2%  | CHILD syndrome, 308050<br>CK syndrome, 300831  |
| NSUN2 | 96.2  | 98.5%  | 94.8%  | Mental retardation, autosomal recessive 5, 611091  |
| NT5C2 | 119.4 | 97.9%  | 95.8%  | Spastic paraplegia 45, autosomal recessive, 613162   |
| NTRK1 | 144.9 | 100.0% | 99.7%  | Medullary thyroid carcinoma, familial, 155240<br>Insensitivity to pain, congenital, with anhidrosis, 256800  |
| NTRK2 | 142.9 | 100.0% | 99.9%  | Obesity, hyperphagia, and developmental delay, 613886<br>Epileptic encephalopathy, early infantile, 58, 617830   |
| NUBPL | 102.4 | 98.9%  | 94.2%  | Mitochondrial complex I deficiency, nuclear type 21, 618242  |
| NUP62 | 124.5 | 100.0% | 100.0% | Striatonigral degeneration, infantile, 271930  |
| NUS1  | 51.9  | 72.8%  | 44.9%  | Mental retardation, autosomal dominant 55, with seizures, 617831<br>?Congenital disorder of glycosylation, type 1aa, 617082  |
| OAT   | 69.1  | 80.2%  | 69.8%  | Gyrate atrophy of choroid and retina with or without ornithinemia, 258870  |
| OCLN  | 179.8 | 100.0% | 100.0% | Pseudo-TORCH syndrome 1, 251290  |
| OCRL  | 106.2 | 99.9%  | 98.6%  | Lowe syndrome, 309000<br>Dent disease 2, 300555  |
| ODC1  | 123.0 | 100.0% | 98.7%  | No OMIM disease ID   |
| OFD1  | 52.3  | 85.5%  | 70.0%  | Orofaciodigital syndrome I, 311200<br>?Retinitis pigmentosa 23, 300424<br>Joubert syndrome 10, 300804<br>Simpson-Golabi-Behmel syndrome, type 2, 300209  |
| OGT   | 108.0 | 99.9%  | 98.7%  | Mental retardation, X-linked 106, 300997   |
| OPHN1 | 80.7  | 99.0%  | 95.5%  | Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486   |
| ORC1  | 93.8  | 99.9%  | 98.9%  | Meier-Gorlin syndrome 1, 224690  |
| OSGEP | 104.4 | 100.0% | 97.8%  | Galloway-Mowat syndrome 3, 617729  |
| OTC   | 111.3 | 100.0% | 99.7%  | Ornithine transcarbamylase deficiency, 311250  |



|          |       |        |        |  |
|----------|-------|--------|--------|--|
| OTUD6B   | 118.1 | 99.9%  | 97.9%  | Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, 617452  |
| OTX2     | 135.4 | 100.0% | 99.6%  | Microphthalmia, syndromic 5, 610125<br>Pituitary hormone deficiency, combined, 6, 613986<br>Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125  |
| P4HTM    | 177.7 | 100.0% | 99.4%  | Hypotonia, hypoventilation, impaired intellectual development, dysautonomia, epilepsy, and eye abnormalities, 618493   |
| PACS1    | 115.1 | 100.0% | 99.8%  | Schuurs-Hoeijmakers syndrome, 615009   |
| PACS2    | 170.7 | 100.0% | 99.6%  | Epileptic encephalopathy, early infantile, 66, 618067  |
| PAFAH1B1 | 78.7  | 91.7%  | 82.7%  | Subcortical laminar heterotopia, 607432<br>Lissencephaly 1, 607432   |
| PAH      | 128.9 | 100.0% | 100.0% | Phenylketonuria, 261600  |
| PAK1     | 102.7 | 100.0% | 99.3%  | Intellectual developmental disorder with macrocephaly, seizures, and speech delay, 618158  |
| PAK3     | 85.7  | 99.0%  | 94.4%  | Mental retardation, X-linked 30/47, 300558   |
| PANK2    | 161.5 | 100.0% | 100.0% | HARP syndrome, 607236<br>Neurodegeneration with brain iron accumulation 1, 234200  |
| PANX1    | 137.7 | 100.0% | 99.9%  | Oocyte maturation defect 7, 618550   |
| PARN     | 127.9 | 100.0% | 99.6%  | Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371<br>Dyskeratosis congenita, autosomal recessive 6, 616353  |
| PAX1     | 212.4 | 98.6%  | 94.1%  | ?Otofaciocervical syndrome 2, 615560   |
| PAX6     | 122.8 | 100.0% | 99.9%  | Optic nerve hypoplasia, 165550<br>?Coloboma, ocular, 120200<br>Foveal hypoplasia 1, 136520<br>Aniridia, 106210<br>Keratitis, 148190<br>Cataract with late-onset corneal dystrophy, 106210<br>?Coloboma of optic nerve, 120430<br>?Morning glory disc anomaly, 120430<br>Anterior segment dysgenesis 5, multiple subtypes, 604229 |
| PAX7     | 147.9 | 100.0% | 100.0% | Myopathy, congenital, progressive, with scoliosis, 618578<br>Rhabdomyosarcoma 2, alveolar, 268220  |
| PAX8     | 103.2 | 100.0% | 100.0% | Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700  |
| PBX1     | 115.4 | 100.0% | 98.3%  | Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay, 617641  |
| PC       | 170.2 | 99.9%  | 98.8%  | Pyruvate carboxylase deficiency, 266150  |
| PCCA     | 97.7  | 99.1%  | 95.4%  | Propionicacidemia, 606054  |
| PCCB     | 114.9 | 99.5%  | 97.1%  | Propionicacidemia, 606054  |
| PCDH12   | 195.1 | 100.0% | 100.0% | Diencephalic-mesencephalic junction dysplasia syndrome 1, 251280   |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| PCDH19 | 192.4 | 99.9%  | 98.9%  | Epileptic encephalopathy, early infantile, 9, 300088   |
| PCGF2  | 103.7 | 99.8%  | 97.3%  | Turnpenny-Fry syndrome, 618371   |
| PCLO   | 147.8 | 99.9%  | 99.0%  | ?Pontocerebellar hypoplasia, type 3, 608027  |
| PCNT   | 124.1 | 99.8%  | 98.2%  | Microcephalic osteodysplastic primordial dwarfism, type II, 210720   |
| PDE4D  | 104.9 | 95.8%  | 95.0%  | Acrodysostosis 2, with or without hormone resistance, 614613   |
| PDHA1  | 88.0  | 98.6%  | 95.4%  | Pyruvate dehydrogenase E1-alpha deficiency, 312170   |
| PDHX   | 132.4 | 100.0% | 99.5%  | Lacticacidemia due to PDX1 deficiency, 245349  |
| PDP1   | 134.9 | 100.0% | 100.0% | Pyruvate dehydrogenase phosphatase deficiency, 608782  |
| PDSS1  | 106.9 | 97.6%  | 88.2%  | Coenzyme Q10 deficiency, primary, 2, 614651  |
| PDSS2  | 115.4 | 99.3%  | 95.2%  | Coenzyme Q10 deficiency, primary, 3, 614652  |
| PEPD   | 126.5 | 100.0% | 99.9%  | Prolidase deficiency, 170100   |
| PET100 | 95.2  | 99.7%  | 90.6%  | Mitochondrial complex IV deficiency, 220110  |
| PEX1   | 126.3 | 100.0% | 99.1%  | Heimler syndrome 1, 234580<br>Peroxisome biogenesis disorder 1B (NALD/IRD), 601539<br>Peroxisome biogenesis disorder 1A (Zellweger), 214100                |
| PEX10  | 123.8 | 100.0% | 98.4%  | Peroxisome biogenesis disorder 6B, 614871<br>Peroxisome biogenesis disorder 6A (Zellweger), 614870   |
| PEX11B | 93.3  | 100.0% | 99.9%  | ?Peroxisome biogenesis disorder 14B, 614920  |
| PEX12  | 125.4 | 100.0% | 100.0% | Peroxisome biogenesis disorder 3A (Zellweger), 614859<br>Peroxisome biogenesis disorder 3B, 266510   |
| PEX13  | 189.6 | 100.0% | 100.0% | Peroxisome biogenesis disorder 11A (Zellweger), 614883<br>Peroxisome biogenesis disorder 11B, 614885   |
| PEX16  | 157.0 | 98.9%  | 95.7%  | Peroxisome biogenesis disorder 8A (Zellweger), 614876<br>Peroxisome biogenesis disorder 8B, 614877   |
| PEX19  | 85.8  | 100.0% | 98.9%  | Peroxisome biogenesis disorder 12A (Zellweger), 614886   |
| PEX2   | 137.4 | 100.0% | 100.0% | Peroxisome biogenesis disorder 5A (Zellweger), 614866<br>Peroxisome biogenesis disorder 5B, 614867   |
| PEX26  | 105.1 | 100.0% | 100.0% | Peroxisome biogenesis disorder 7A (Zellweger), 614872<br>Peroxisome biogenesis disorder 7B, 614873   |
| PEX3   | 108.6 | 100.0% | 99.6%  | Peroxisome biogenesis disorder 10A (Zellweger), 614882<br>?Peroxisome biogenesis disorder 10B, 617370  |
| PEX5   | 115.8 | 100.0% | 99.4%  | Peroxisome biogenesis disorder 2B, 202370<br>Rhizomelic chondrodysplasia punctata, type 5, 616716<br>Peroxisome biogenesis disorder 2A (Zellweger), 214110 |
| PEX6   | 117.6 | 99.1%  | 93.9%  | Peroxisome biogenesis disorder 4B, 614863<br>Heimler syndrome 2, 616617<br>Peroxisome biogenesis disorder 4A (Zellweger), 614862                           |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| PEX7    | 108.8 | 91.3%  | 91.0%  | Peroxisome biogenesis disorder 9B, 614879<br>Rhizomelic chondrodysplasia punctata, type 1, 215100   |
| PGAP1   | 106.2 | 98.8%  | 94.3%  | Mental retardation, autosomal recessive 42, 615802  |
| PGAP2   | 145.1 | 100.0% | 99.8%  | Hyperphosphatasia with mental retardation syndrome 3, 614207  |
| PGAP3   | 74.5  | 63.7%  | 60.6%  | Hyperphosphatasia with mental retardation syndrome 4, 615716  |
| PGK1    | 47.0  | 92.1%  | 78.7%  | Phosphoglycerate kinase 1 deficiency, 300653  |
| PGM3    | 148.4 | 100.0% | 99.9%  | Immunodeficiency 23, 615816   |
| PHACTR1 | 111.1 | 100.0% | 99.8%  | Epileptic encephalopathy, early infantile, 70, 618298   |
| PHF21A  | 97.3  | 100.0% | 99.5%  | No OMIM Disease ID  |
| PHF6    | 57.7  | 96.9%  | 84.1%  | Borjeson-Forssman-Lehmann syndrome, 301900  |
| PHF8    | 78.0  | 99.5%  | 96.1%  | Mental retardation syndrome, X-linked, Siderius type, 300263  |
| PHGDH   | 116.2 | 100.0% | 99.6%  | Neu-Laxova syndrome 1, 256520<br>Phosphoglycerate dehydrogenase deficiency, 601815  |
| PHIP    | 126.6 | 99.4%  | 96.6%  | Chung-Jansen syndrome, 617991   |
| PI4KA   | 95.6  | 94.4%  | 90.4%  | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, 616531  |
| PIGA    | 72.9  | 93.0%  | 83.4%  | Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868<br>Paroxysmal nocturnal hemoglobinuria, somatic, 300818   |
| PIGB    | 94.8  | 99.1%  | 93.8%  | Epileptic encephalopathy, early infantile, 80, 618580   |
| PIGC    | 91.5  | 99.9%  | 95.9%  | Glycosylphosphatidylinositol biosynthesis defect 16, 617816   |
| PIGG    | 149.1 | 100.0% | 99.8%  | Mental retardation, autosomal recessive 53, 616917  |
| PIGL    | 132.2 | 100.0% | 99.1%  | CHIME syndrome, 280000  |
| PIGN    | 103.7 | 93.6%  | 90.1%  | Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080   |
| PIGO    | 157.3 | 100.0% | 100.0% | Hyperphosphatasia with mental retardation syndrome 2, 614749  |
| PIGP    | 88.3  | 95.6%  | 86.3%  | ?Epileptic encephalopathy, early infantile, 55, 617599  |
| PIGT    | 169.4 | 98.1%  | 98.1%  | ?Paroxysmal nocturnal hemoglobinuria 2, 615399<br>Multiple congenital anomalies-hypotonia-seizures syndrome 3, 615398   |
| PIGU    | 93.2  | 99.8%  | 98.2%  | Glycosylphosphatidylinositol biosynthesis defect 21, 618590   |
| PIGV    | 129.3 | 100.0% | 100.0% | Hyperphosphatasia with mental retardation syndrome 1, 239300  |
| PIGW    | 144.9 | 100.0% | 99.8%  | Glycosylphosphatidylinositol biosynthesis defect 11, 616025   |
| PIGY    | 89.9  | 100.0% | 100.0% | Hyperphosphatasia with mental retardation syndrome 6, 616809  |
| PIK3CA  | 122.5 | 100.0% | 99.8%  | Ovarian cancer, somatic, 167000<br>Colorectal cancer, somatic, 114500<br>CLAPO syndrome, somatic, 613089<br>Cowden syndrome 5, 615108<br>Hepatocellular carcinoma, somatic, 114550<br>Breast cancer, somatic, 114480<br>Macrodactyly, somatic, 155500 |

|        |       |        |        |   |
|--------|-------|--------|--------|---|
|        |       |        |        | Keratosis, seborrheic, somatic, 182000<br>Gastric cancer, somatic, 613659<br>Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501<br>Nevus, epidermal, somatic, 162900<br>CLOVE syndrome, somatic, 612918<br>Nonsmall cell lung cancer, somatic, 211980   |
| PIK3R2 | 115.8 | 95.4%  | 91.8%  | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387  |
| PLA2G6 | 121.0 | 99.9%  | 98.6%  | Infantile neuroaxonal dystrophy 1, 256600<br>Parkinson disease 14, autosomal recessive, 612953<br>Neurodegeneration with brain iron accumulation 2B, 610217   |
| PLAA   | 162.9 | 99.9%  | 98.4%  | Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, 617527  |
| PLCB1  | 134.5 | 100.0% | 99.8%  | Epileptic encephalopathy, early infantile, 12, 613722   |
| PLK4   | 145.8 | 99.9%  | 98.1%  | Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171  |
| PLP1   | 113.6 | 99.9%  | 98.2%  | Pelizaeus-Merzbacher disease, 312080<br>Spastic paraplegia 2, X-linked, 312920  |
| PLPBP  | 97.2  | 99.9%  | 97.2%  | Epilepsy, early-onset, vitamin B6-dependent, 617290   |
| PLXND1 | 134.9 | 99.8%  | 98.5%  | No OMIM Disease ID  |
| PMM2   | 130.3 | 100.0% | 99.7%  | Congenital disorder of glycosylation, type Ia, 212065   |
| PMPCA  | 113.3 | 99.6%  | 97.1%  | Spinocerebellar ataxia, autosomal recessive 2, 213200   |
| PMPCB  | 121.6 | 100.0% | 99.3%  | Multiple mitochondrial dysfunctions syndrome 6, 617954  |
| PNKP   | 123.1 | 100.0% | 100.0% | Ataxia-oculomotor apraxia 4, 616267<br>Microcephaly, seizures, and developmental delay, 613402  |
| PNP    | 113.1 | 100.0% | 99.8%  | Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179  |
| PNPLA6 | 153.1 | 100.0% | 99.6%  | Spastic paraplegia 39, autosomal recessive, 612020<br>Boucher-Neuhauser syndrome, 215470<br>Oliver-McFarlane syndrome, 275400<br>?Laurence-Moon syndrome, 245800  |
| POGZ   | 129.7 | 99.5%  | 99.2%  | White-Sutton syndrome, 616364   |
| POLA1  | 104.7 | 99.1%  | 94.7%  | Pigmentary disorder, reticulate, with systemic manifestations, X-linked, 301220<br>Van Esch-O'Driscoll syndrome, 301030   |
| POLG   | 124.4 | 100.0% | 99.8%  | Progressive external ophthalmoplegia, autosomal dominant 1, 157640<br>Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662<br>Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459<br>Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700<br>Progressive external ophthalmoplegia, autosomal recessive 1, 258450 |
| POLR2A | 176.1 | 100.0% | 100.0% | Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, 618603   |
| POLR3A | 119.8 | 100.0% | 99.9%  | Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694<br>Wiedemann-Rautenstrauch syndrome, 264090  |

|          |       |        |        |  |
|----------|-------|--------|--------|--|
| POLR3B   | 132.0 | 99.9%  | 98.3%  | Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381   |
| POMGNT1  | 123.6 | 100.0% | 99.8%  | Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151<br>Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157<br>Retinitis pigmentosa 76, 617123<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 |
| POMGNT2  | 225.4 | 100.0% | 100.0% | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830<br>Muscular dystrophy-dystroglycanopathy (limb-girdle) type C, 8, 618135   |
| POMK     | 144.2 | 100.0% | 100.0% | ?Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12, 616094<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249  |
| POMT1    | 137.5 | 99.6%  | 97.8%  | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670<br>Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155                                    |
| POMT2    | 109.7 | 100.0% | 99.1%  | Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158<br>Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150<br>Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156                                    |
| PORCN    | 119.6 | 99.9%  | 98.9%  | Focal dermal hypoplasia, 305600  |
| POU1F1   | 109.5 | 99.9%  | 98.2%  | Pituitary hormone deficiency, combined, 1, 613038  |
| POU3F3   | 65.0  | 90.8%  | 76.5%  | Snijders Blok-Fisher syndrome, 618604  |
| PPM1D    | 177.2 | 100.0% | 99.8%  | Breast cancer, somatic, 114480<br>Jansen de Vries syndrome, 617450   |
| PPP1CB   | 110.7 | 100.0% | 99.6%  | Noonan syndrome-like disorder with loose anagen hair 2, 617506   |
| PPP1R15B | 130.2 | 100.0% | 100.0% | Microcephaly, short stature, and impaired glucose metabolism 2, 616817   |
| PPP1R21  | 128.6 | 99.8%  | 98.1%  | No OMIM Disease ID   |
| PPP2CA   | 166.7 | 100.0% | 100.0% | Neurodevelopmental disorder and language delay with or without structural brain abnormalities, 618354  |
| PPP2R1A  | 138.5 | 91.6%  | 91.6%  | Mental retardation, autosomal dominant 36, 616362  |
| PPP2R5B  | 127.3 | 100.0% | 100.0% | No OMIM Disease ID   |
| PPP2R5C  | 98.9  | 97.1%  | 89.4%  | No OMIM Disease ID   |
| PPP2R5D  | 145.7 | 100.0% | 100.0% | Mental retardation, autosomal dominant 35, 616355  |
| PPP3CA   | 120.5 | 99.8%  | 97.5%  | Epileptic encephalopathy, infantile or early childhood, 1, 617711<br>Arthrogyriposis, cleft palate, craniosynostosis, and impaired intellectual development, 618265  |
| PPT1     | 140.2 | 90.3%  | 89.2%  | Ceroid lipofuscinosis, neuronal, 1, 256730   |
| PQBP1    | 173.3 | 100.0% | 100.0% | Renpenning syndrome, 309500  |
| PRKAR1A  | 80.5  | 98.1%  | 92.8%  | Myxoma, intracardiac, 255960<br>Carney complex, type 1, 160980<br>Pigmented nodular adrenocortical disease, primary, 1, 610489<br>Acrodysostosis 1, with or without hormone resistance, 101800<br>Adrenocortical tumor, somatic, 0   |

|        |       |        |        |   |
|--------|-------|--------|--------|---|
| PRMT7  | 128.8 | 100.0% | 99.9%  | Short stature, brachydactyly, intellectual developmental disability, and seizures, 617157   |
| PRODH  | 88.9  | 91.8%  | 83.0%  | Hyperprolinemia, type I, 239500   |
| PRPS1  | 113.2 | 100.0% | 99.9%  | Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070<br>Phosphoribosylpyrophosphate synthetase superactivity, 300661<br>Deafness, X-linked 1, 304500<br>Arts syndrome, 301835<br>Gout, PRPS-related, 300661 |
| PRR12  | 146.7 | 100.0% | 98.4%  | No OMIM Disease ID  |
| PRSS12 | 144.0 | 100.0% | 99.8%  | Mental retardation, autosomal recessive 1, 249500   |
| PRUNE1 | 120.3 | 100.0% | 99.6%  | Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, 617481  |
| PSAP   | 103.3 | 100.0% | 99.5%  | Gaucher disease, atypical, 610539<br>Krabbe disease, atypical, 611722<br>Combined SAP deficiency, 611721<br>Metachromatic leukodystrophy due to SAP-b deficiency, 249900  |
| PSAT1  | 46.2  | 91.6%  | 74.2%  | Neu-Laxova syndrome 2, 616038<br>?Phosphoserine aminotransferase deficiency, 610992   |
| PSMD12 | 87.5  | 98.2%  | 90.2%  | Stankiewicz-Isidor syndrome, 617516   |
| PSPH   | 122.1 | 100.0% | 99.8%  | Phosphoserine phosphatase deficiency, 614023  |
| PTCH1  | 117.3 | 100.0% | 99.2%  | Basal cell carcinoma, somatic, 605462<br>Basal cell nevus syndrome, 109400<br>Holoprosencephaly 7, 610828   |
| PTCHD1 | 143.0 | 100.0% | 100.0% | No OMIM disease ID  |
| PTDSS1 | 116.2 | 100.0% | 100.0% | Lenz-Majewski hyperostotic dwarfism, 151050   |
| PTEN   | 125.3 | 99.7%  | 95.5%  | Prostate cancer, somatic, 176807<br>Cowden syndrome 1, 158350<br>Lhermitte-Duclos syndrome, 158350<br>Macrocephaly/autism syndrome, 605309  |
| PTF1A  | 138.4 | 100.0% | 99.7%  | Pancreatic and cerebellar agenesis, 609069<br>Pancreatic agenesis 2, 615935   |
| PTPN11 | 80.5  | 98.8%  | 91.3%  | LEOPARD syndrome 1, 151100<br>Metachondromatosis, 156250<br>Noonan syndrome 1, 163950<br>Leukemia, juvenile myelomonocytic, somatic, 607785   |
| PTRH2  | 209.0 | 100.0% | 100.0% | Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263   |
| PTRHD1 | 205.4 | 100.0% | 100.0% | No OMIM Disease ID  |
| PTS    | 103.1 | 100.0% | 98.3%  | Hyperphenylalaninemia, BH4-deficient, A, 261640   |
| PUF60  | 178.6 | 100.0% | 99.6%  | Verheij syndrome, 615583  |
| PUM1   | 132.0 | 100.0% | 99.7%  | Spinocerebellar ataxia 47, 617931   |

|          |       |        |        |  |
|----------|-------|--------|--------|--|
| PURA     | 233.4 | 99.9%  | 98.8%  | Mental retardation, autosomal dominant 31, 616158  |
| PUS1     | 125.7 | 99.8%  | 98.1%  | Myopathy, lactic acidosis, and sideroblastic anemia 1, 600462  |
| PUS3     | 163.9 | 100.0% | 100.0% | Mental retardation, autosomal recessive 55, 617051   |
| PUS7     | 134.7 | 100.0% | 99.5%  | Intellectual developmental disorder with abnormal behavior, microcephaly, and short stature, 618342      |
| PYCR1    | 105.0 | 100.0% | 99.0%  | Cutis laxa, autosomal recessive, type IIIB, 614438<br>Cutis laxa, autosomal recessive, type IIB, 612940  |
| PYCR2    | 129.0 | 99.7%  | 97.6%  | Leukodystrophy, hypomyelinating, 10, 616420  |
| QARS     | 137.7 | 100.0% | 100.0% | Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760                         |
| QDPR     | 103.7 | 99.9%  | 99.1%  | Hyperphenylalaninemia, BH4-deficient, C, 261630  |
| QRICH1   | 142.0 | 100.0% | 99.6%  | Ververi-Brady syndrome, 617982   |
| RAB11B   | 229.2 | 100.0% | 100.0% | Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter, 617807 |
| RAB18    | 80.5  | 99.7%  | 95.3%  | Warburg micro syndrome 3, 614222   |
| RAB23    | 102.4 | 100.0% | 99.8%  | Carpenter syndrome, 201000   |
| RAB27A   | 123.3 | 100.0% | 99.6%  | Griscelli syndrome, type 2, 607624   |
| RAB39B   | 108.8 | 100.0% | 100.0% | Waisman syndrome, 311510<br>Mental retardation, X-linked 72, 300271                                      |
| RAB3GAP1 | 123.3 | 99.4%  | 98.8%  | Warburg micro syndrome 1, 600118   |
| RAB3GAP2 | 89.9  | 99.7%  | 96.1%  | Warburg micro syndrome 2, 614225<br>Martsof syndrome, 212720   |
| RAC1     | 108.4 | 99.5%  | 95.4%  | Mental retardation, autosomal dominant 48, 617751  |
| RAC3     | 132.6 | 98.1%  | 95.4%  | Neurodevelopmental disorder with structural brain anomalies and dysmorphic facies, 618577                |
| RAD21    | 80.8  | 98.0%  | 93.5%  | ?Mungan syndrome, 611376<br>Cornelia de Lange syndrome 4, 614701   |
| RAF1     | 111.1 | 100.0% | 99.9%  | LEOPARD syndrome 2, 611554<br>Noonan syndrome 5, 611553<br>Cardiomyopathy, dilated, 1NN, 615916          |
| RAI1     | 216.5 | 100.0% | 100.0% | Smith-Magenis syndrome, 182290   |
| RALA     | 123.4 | 89.9%  | 82.9%  | No OMIM Disease ID   |
| RARB     | 93.5  | 100.0% | 100.0% | Microphthalmia, syndromic 12, 615524   |
| RARS     | 93.8  | 93.3%  | 88.0%  | Leukodystrophy, hypomyelinating, 9, 616140   |
| RARS2    | 102.7 | 100.0% | 99.3%  | Pontocerebellar hypoplasia, type 6, 611523   |
| RBBP8    | 117.9 | 100.0% | 99.3%  | Jawad syndrome, 251255<br>Seckel syndrome 2, 606744<br>Pancreatic carcinoma, somatic, 0                  |
| RBFOX1   | 145.4 | 90.6%  | 89.1%  | No OMIM Disease ID   |
| RBM10    | 122.0 | 99.9%  | 98.5%  | TARP syndrome, 311900  |
| RBM28    | 132.1 | 100.0% | 100.0% | ?Alopecia, neurologic defects, and endocrinopathy syndrome, 612079                                       |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| RBPJ     | 72.1  | 95.8%  | 87.2%  | Adams-Oliver syndrome 3, 614814   |
| RCBTB1   | 98.4  | 99.9%  | 99.0%  | Retinal dystrophy with or without extraocular anomalies, 617175   |
| RECQL4   | 181.4 | 100.0% | 100.0% | RAPADILINO syndrome, 266280<br>Baller-Gerold syndrome, 218600<br>Rothmund-Thomson syndrome, type 2,, 268400               |
| RELN     | 131.8 | 100.0% | 99.6%  | Lissencephaly 2 (Norman-Roberts type), 257320   |
| RERE     | 84.5  | 96.9%  | 94.3%  | Neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, 616975                                 |
| REV3L    | 137.7 | 97.6%  | 97.1%  | No OMIM Disease ID  |
| RFT1     | 106.6 | 100.0% | 99.2%  | Congenital disorder of glycosylation, type In, 612015   |
| RHEB     | 35.8  | 94.1%  | 71.9%  | No OMIM Disease ID  |
| RHOBTB2  | 206.4 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 64, 618004   |
| RIT1     | 142.5 | 100.0% | 100.0% | Noonan syndrome 8, 615355   |
| RLIM     | 99.8  | 99.7%  | 97.7%  | Tonne-Kalscheuer syndrome, 300978   |
| RMND1    | 130.7 | 100.0% | 99.0%  | Combined oxidative phosphorylation deficiency 11, 614922  |
| RMRP     | NC    | NC     | NC     | Anauxetic dysplasia 1, 607095<br>Cartilage-hair hypoplasia, 250250<br>Metaphyseal dysplasia without hypotrichosis, 250460 |
| RNASEH2A | 143.0 | 100.0% | 100.0% | Aicardi-Goutieres syndrome 4, 610333  |
| RNASEH2B | 98.0  | 99.8%  | 96.3%  | Aicardi-Goutieres syndrome 2, 610181  |
| RNASEH2C | 314.2 | 100.0% | 100.0% | Aicardi-Goutieres syndrome 3, 610329  |
| RNASET2  | 109.5 | 95.4%  | 89.8%  | Leukoencephalopathy, cystic, without megalencephaly, 612951   |
| RNF113A  | 149.1 | 100.0% | 100.0% | ?Trichothiodystrophy 5, nonphotosensitive, 300953   |
| RNF125   | 178.2 | 99.9%  | 98.6%  | Tenorio syndrome, 616260  |
| RNF13    | 80.5  | 91.4%  | 71.6%  | Epileptic encephalopathy, early infantile, 73, 618379   |
| ROGDI    | 141.6 | 100.0% | 99.9%  | Kohlschutter-Tonz syndrome, 226750  |
| ROR2     | 176.7 | 100.0% | 99.9%  | Brachydactyly, type B1, 113000<br>Robinow syndrome, autosomal recessive, 268310   |
| RORA     | 105.6 | 97.1%  | 91.6%  | Intellectual developmental disorder with or without epilepsy or cerebellar ataxia, 618060                                 |
| RPGRIP1L | 124.2 | 96.8%  | 95.8%  | COACH syndrome, 216360<br>Meckel syndrome 5, 611561<br>Joubert syndrome 7, 611560   |
| RPL10    | 68.6  | 98.5%  | 89.7%  | Mental retardation, X-linked, syndromic, 35, 300998   |
| RPS19    | 81.5  | 100.0% | 98.3%  | Diamond-Blackfan anemia 1, 105650   |
| RPS6KA3  | 84.8  | 98.2%  | 91.5%  | Mental retardation, X-linked 19, 300844<br>Coffin-Lowry syndrome, 303600  |



|         |       |        |        |   |
|---------|-------|--------|--------|---|
| RRM2B   | 142.6 | 100.0% | 99.4%  | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5, 613077<br>Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075<br>Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 |
| RSPRY1  | 143.3 | 100.0% | 100.0% | Spondyloepimetaphyseal dysplasia, Faden-Alkuraya type, 616723   |
| RSRC1   | 74.3  | 99.1%  | 94.6%  | Intellectual developmental disorder, autosomal recessive 70, 618402   |
| RTEL1   | 145.6 | 99.8%  | 98.2%  | Dyskeratosis congenita, autosomal recessive 5, 615190<br>Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3, 616373<br>Dyskeratosis congenita, autosomal dominant 4, 615190   |
| RTN4IP1 | 80.2  | 99.6%  | 98.2%  | Optic atrophy 10 with or without ataxia, mental retardation, and seizures, 616732   |
| RTTN    | 117.3 | 98.6%  | 97.3%  | Microcephaly, short stature, and polymicrogyria with seizures, 614833   |
| RUBCN   | 105.3 | 100.0% | 99.5%  | ?Spinocerebellar ataxia, autosomal recessive 15, 615705   |
| RUSC2   | 208.1 | 100.0% | 100.0% | Mental retardation, autosomal recessive 61, 617773  |
| SALL1   | 127.8 | 99.9%  | 99.3%  | Townes-Brocks syndrome 1, 107480<br>Townes-Brocks branchiootorenal-like syndrome, 107480  |
| SAMD9   | 161.7 | 100.0% | 100.0% | MIRAGE syndrome, 617053<br>Tumoral calcinosis, familial, normophosphatemic, 610455  |
| SAMHD1  | 135.4 | 100.0% | 98.7%  | ?Chilblain lupus 2, 614415<br>Aicardi-Goutieres syndrome 5, 612952  |
| SARS    | 112.1 | 100.0% | 99.2%  | ?Neurodevelopmental disorder with microcephaly, ataxia, and seizures, 617709  |
| SATB2   | 115.6 | 99.9%  | 98.3%  | Glass syndrome, 612313  |
| SBDS    | 167.5 | 100.0% | 100.0% | Shwachman-Diamond syndrome, 260400  |
| SC5D    | 149.4 | 100.0% | 99.6%  | Lathosterolosis, 607330   |
| SCAMP5  | 111.9 | 100.0% | 100.0% | No OMIM Disease ID  |
| SCAPER  | 137.7 | 97.8%  | 96.0%  | Intellectual developmental disorder and retinitis pigmentosa, 618195  |
| SCN1A   | 120.1 | 99.9%  | 99.0%  | Febrile seizures, familial, 3A, 604403<br>Migraine, familial hemiplegic, 3, 609634<br>Epilepsy, generalized, with febrile seizures plus, type 2, 604403<br>Epileptic encephalopathy, early infantile, 6 (Dravet syndrome), 607208                                       |
| SCN1B   | 186.5 | 100.0% | 99.3%  | Epileptic encephalopathy, early infantile, 52, 617350<br>Atrial fibrillation, familial, 13, 615377<br>Cardiac conduction defect, nonspecific, 612838<br>Epilepsy, generalized, with febrile seizures plus, type 1, 604233<br>Brugada syndrome 5, 612838                 |
| SCN2A   | 135.0 | 99.5%  | 97.4%  | Epileptic encephalopathy, early infantile, 11, 613721<br>Seizures, benign familial infantile, 3, 607745   |
| SCN3A   | 139.1 | 99.9%  | 98.8%  | Epilepsy, familial focal, with variable foci 4, 617935<br>Epileptic encephalopathy, early infantile, 62, 617938   |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| SCN8A   | 162.9 | 100.0% | 99.9%  | Seizures, benign familial infantile, 5, 617080<br>Cognitive impairment with or without cerebellar ataxia, 614306<br>?Myoclonus, familial, 2, 618364<br>Epileptic encephalopathy, early infantile, 13, 614558 |
| SCO1    | 105.2 | 100.0% | 99.6%  | Mitochondrial complex IV deficiency, 220110  |
| SCO2    | 134.9 | 100.0% | 100.0% | Myopia 6, 608908<br>Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377   |
| SCYL1   | 161.4 | 100.0% | 100.0% | Spinocerebellar ataxia, autosomal recessive 21, 616719   |
| SDCCAG8 | 123.5 | 100.0% | 99.7%  | Bardet-Biedl syndrome 16, 615993<br>Senior-Loken syndrome 7, 613615  |
| SDHA    | 94.1  | 85.1%  | 78.0%  | Leigh syndrome, 256000<br>Paragangliomas 5, 614165<br>Cardiomyopathy, dilated, 1GG, 613642<br>Mitochondrial respiratory chain complex II deficiency, 252011  |
| SEMA3E  | 131.0 | 100.0% | 99.7%  | ?CHARGE syndrome, 214800   |
| SEPSECS | 160.6 | 100.0% | 100.0% | Pontocerebellar hypoplasia type 2D, 613811   |
| SERAC1  | 110.4 | 100.0% | 99.0%  | 3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739   |
| SET     | 59.0  | 96.8%  | 89.5%  | Mental retardation, autosomal dominant 58, 618106  |
| SETBP1  | 129.6 | 99.1%  | 97.9%  | Mental retardation, autosomal dominant 29, 616078<br>Schinzel-Giedion midface retraction syndrome, 269150  |
| SETD1A  | 170.3 | 99.8%  | 99.0%  | No OMIM Disease ID   |
| SETD1B  | 192.2 | 97.5%  | 96.6%  | No OMIM Disease ID   |
| SETD2   | 139.1 | 100.0% | 99.7%  | Luscan-Lumish syndrome, 616831   |
| SETD5   | 151.2 | 100.0% | 99.7%  | Mental retardation, autosomal dominant 23, 615761  |
| SGPL1   | 133.4 | 100.0% | 100.0% | Nephrotic syndrome, type 14, 617575  |
| SGSH    | 152.5 | 98.1%  | 94.9%  | Mucopolysaccharidosis type IIIA (Sanfilippo A), 252900   |
| SHANK2  | 152.8 | 100.0% | 99.9%  | No OMIM disease ID   |
| SHANK3  | 143.0 | 98.1%  | 93.8%  | Phelan-McDermid syndrome, 606232   |
| SHH     | 165.7 | 100.0% | 100.0% | Schizencephaly, 269160<br>Microphthalmia with coloboma 5, 611638<br>Single median maxillary central incisor, 147250<br>Holoprosencephaly 3, 142945   |
| SHOC2   | 136.8 | 100.0% | 99.4%  | Noonan syndrome-like with loose anagen hair, 607721  |
| SHROOM4 | 104.6 | 99.9%  | 98.9%  | Stocco dos Santos X-linked mental retardation syndrome, 300434   |
| SIK1    | 131.1 | 99.8%  | 98.1%  | Epileptic encephalopathy, early infantile, 30, 616341  |
| SIL1    | 138.5 | 99.4%  | 96.7%  | Marinesco-Sjogren syndrome, 248800   |
| SIN3A   | 111.6 | 99.9%  | 98.7%  | Witteveen-Kolk syndrome, 613406  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| SIX3     | 240.1 | 100.0% | 100.0% | Holoprosencephaly 2, 157170<br>Schizencephaly, 269160   |
| SKI      | 149.5 | 100.0% | 99.7%  | Shprintzen-Goldberg syndrome, 182212  |
| SLC12A5  | 121.0 | 86.3%  | 84.2%  | Epileptic encephalopathy, early infantile, 34, 616645   |
| SLC12A6  | 120.5 | 100.0% | 100.0% | Agenesis of the corpus callosum with peripheral neuropathy, 218000  |
| SLC13A5  | 155.1 | 100.0% | 99.9%  | Epileptic encephalopathy, early infantile, 25, 615905   |
| SLC16A2  | 67.9  | 99.1%  | 93.5%  | Allan-Herndon-Dudley syndrome, 300523   |
| SLC17A5  | 136.7 | 98.7%  | 95.1%  | Sialic acid storage disorder, infantile, 269920<br>Salla disease, 604369  |
| SLC19A3  | 139.2 | 100.0% | 99.9%  | Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483   |
| SLC1A1   | 149.2 | 100.0% | 99.7%  | Dicarboxylic aminoaciduria, 222730  |
| SLC1A2   | 100.8 | 99.5%  | 97.2%  | Epileptic encephalopathy, early infantile, 41, 617105   |
| SLC1A4   | 159.5 | 100.0% | 99.8%  | Spastic tetraplegia, thin corpus callosum, and progressive microcephaly, 616657   |
| SLC25A1  | 114.2 | 99.8%  | 97.0%  | ?Myasthenic syndrome, congenital, 23, presynaptic, 618197<br>Combined D-2- and L-2-hydroxyglutaric aciduria, 615182   |
| SLC25A12 | 151.7 | 100.0% | 99.7%  | Epileptic encephalopathy, early infantile, 39, 612949   |
| SLC25A15 | 152.1 | 98.4%  | 94.4%  | Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970   |
| SLC25A22 | 138.5 | 100.0% | 99.7%  | Epileptic encephalopathy, early infantile, 3, 609304  |
| SLC25A24 | 133.1 | 99.7%  | 99.5%  | Fontaine progeroid syndrome, 612289   |
| SLC2A1   | 160.0 | 92.8%  | 92.8%  | Dystonia 9, 601042<br>GLUT1 deficiency syndrome 1, infantile onset, severe, 606777<br>Stomatin-deficient cryohydrocytosis with neurologic defects, 608885<br>GLUT1 deficiency syndrome 2, childhood onset, 612126 |
| SLC33A1  | 135.7 | 99.8%  | 97.0%  | Spastic paraplegia 42, autosomal dominant, 612539<br>Congenital cataracts, hearing loss, and neurodegeneration, 614482  |
| SLC35A1  | 123.5 | 100.0% | 99.8%  | Congenital disorder of glycosylation, type II f, 603585   |
| SLC35A2  | 114.2 | 100.0% | 99.1%  | Congenital disorder of glycosylation, type II m, 300896   |
| SLC35A3  | 63.5  | 80.4%  | 77.0%  | ?Arthrogryposis, mental retardation, and seizures, 615553   |
| SLC35C1  | 209.1 | 100.0% | 99.9%  | Congenital disorder of glycosylation, type II c, 266265   |
| SLC39A14 | 101.7 | 99.9%  | 98.8%  | ?Hyperostosis cranialis interna, 144755<br>Hypermanganesemia with dystonia 2, 617013  |
| SLC39A8  | 144.7 | 100.0% | 99.8%  | Congenital disorder of glycosylation, type II n, 616721   |
| SLC46A1  | 121.7 | 100.0% | 98.0%  | Folate malabsorption, hereditary, 229050  |
| SLC4A4   | 114.4 | 99.8%  | 97.9%  | Renal tubular acidosis, proximal, with ocular abnormalities, 604278   |
| SLC6A1   | 136.0 | 100.0% | 100.0% | Myoclonic-atonic epilepsy, 616421   |
| SLC6A17  | 162.2 | 100.0% | 100.0% | Mental retardation, autosomal recessive 48, 616269  |

|          |       |        |        |   |
|----------|-------|--------|--------|---|
| SLC6A19  | 139.1 | 100.0% | 100.0% | Iminoglycinuria, digenic, 242600<br>Hartnup disorder, 234500<br>Hyperglycinuria, 138500   |
| SLC6A3   | 142.7 | 100.0% | 99.9%  | Parkinsonism-dystonia, infantile, 1, 613135   |
| SLC6A8   | 58.5  | 97.6%  | 87.8%  | Cerebral creatine deficiency syndrome 1, 300352   |
| SLC6A9   | 164.3 | 100.0% | 100.0% | Glycine encephalopathy with normal serum glycine, 617301  |
| SLC7A7   | 110.7 | 100.0% | 99.8%  | Lysinuric protein intolerance, 222700   |
| SLC9A6   | 104.0 | 98.5%  | 93.3%  | Mental retardation, X-linked syndromic, Christianson type, 300243   |
| SLC9A7   | 87.8  | 98.1%  | 92.1%  | Intellectual developmental disorder, X-linked 108, 301024   |
| SMAD4    | 109.9 | 100.0% | 99.9%  | Polyposis, juvenile intestinal, 174900<br>Myhre syndrome, 139210<br>Pancreatic cancer, somatic, 260350<br>Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 |
| SMARCA1  | 90.8  | 99.4%  | 95.0%  | No OMIM Disease ID  |
| SMARCA2  | 109.3 | 97.3%  | 96.3%  | Nicolaides-Baraitser syndrome, 601358   |
| SMARCA4  | 163.9 | 100.0% | 99.6%  | Coffin-Siris syndrome 4, 614609   |
| SMARCB1  | 192.9 | 100.0% | 100.0% | Rhabdoid tumors, somatic, 609322<br>Coffin-Siris syndrome 3, 614608   |
| SMARCC2  | 104.2 | 99.9%  | 98.7%  | Coffin-Siris syndrome 8, 618362   |
| SMARCD1  | 116.1 | 97.4%  | 91.7%  | No OMIM Disease ID  |
| SMARCE1  | 66.9  | 94.6%  | 85.4%  | Coffin-Siris syndrome 5, 616938   |
| SMC1A    | 93.2  | 99.9%  | 98.3%  | Cornelia de Lange syndrome 2, 300590  |
| SMC3     | 82.8  | 96.4%  | 89.7%  | Cornelia de Lange syndrome 3, 610759  |
| SMG9     | 100.1 | 100.0% | 100.0% | Heart and brain malformation syndrome, 616920   |
| SMOC1    | 121.2 | 99.9%  | 98.4%  | Microphthalmia with limb anomalies, 206920  |
| SMPD1    | 161.8 | 100.0% | 99.6%  | Niemann-Pick disease, type A, 257200<br>Niemann-Pick disease, type B, 607616  |
| SMPD4    | 108.3 | 99.9%  | 96.9%  | Neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, 618622   |
| SMS      | 63.5  | 88.9%  | 74.1%  | Mental retardation, X-linked, Snyder-Robinson type, 309583  |
| SNAP25   | 121.8 | 100.0% | 99.7%  | ?Myasthenic syndrome, congenital, 18, 616330  |
| SNAP29   | 182.5 | 100.0% | 100.0% | Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528  |
| SNIP1    | 140.1 | 100.0% | 99.6%  | Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501   |
| SNORD118 | NC    | NC     | NC     | Leukoencephalopathy, brain calcifications, and cysts, 614561  |
| SNRPB    | 83.6  | 99.9%  | 98.8%  | Cerebrocostomandibular syndrome, 117650   |
| SNRPN    | 98.3  | 100.0% | 98.4%  | Prader-Willi syndrome, 176270   |
| SNX14    | 79.9  | 99.7%  | 93.7%  | Spinocerebellar ataxia, autosomal recessive 20, 616354  |
| SOBP     | 199.7 | 98.9%  | 98.8%  | Mental retardation, anterior maxillary protrusion, and strabismus, 613671   |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| SON     | 134.3 | 99.2%  | 95.4%  | ZTTK syndrome, 617140   |
| SOS1    | 100.6 | 99.7%  | 96.7%  | Noonan syndrome 4, 610733<br>?Fibromatosis, gingival, 1, 135300   |
| SOS2    | 98.0  | 99.7%  | 97.7%  | Noonan syndrome 9, 616559   |
| SOX10   | 101.7 | 100.0% | 99.8%  | Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584<br>PCWH syndrome, 609136<br>Waardenburg syndrome, type 4C, 613266                 |
| SOX11   | 225.3 | 100.0% | 100.0% | Coffin-Siris syndrome 9, 615866   |
| SOX2    | 261.8 | 100.0% | 100.0% | Microphthalmia, syndromic 3, 206900<br>Optic nerve hypoplasia and abnormalities of the central nervous system, 206900   |
| SOX3    | 87.5  | 99.0%  | 95.2%  | Panhypopituitarism, X-linked, 312000<br>Mental retardation, X-linked, with isolated growth hormone deficiency, 300123   |
| SOX4    | 122.0 | 100.0% | 99.9%  | Coffin-Siris syndrome 10, 618506  |
| SOX5    | 92.0  | 99.8%  | 96.6%  | Lamb-Shaffer syndrome, 616803   |
| SPART   | 132.9 | 100.0% | 98.4%  | Troyer syndrome, 275900   |
| SPAST   | 94.9  | 99.7%  | 96.9%  | Spastic paraplegia 4, autosomal dominant, 182601  |
| SPATA5  | 142.5 | 100.0% | 99.8%  | Epilepsy, hearing loss, and mental retardation syndrome, 616577   |
| SPECC1L | 133.2 | 100.0% | 99.7%  | Hypertelorism, Teebi type, 145420<br>?Facial clefting, oblique, 1, 600251<br>Opitz GBBB syndrome, type II, 145410   |
| SPG11   | 118.8 | 99.9%  | 98.5%  | Charcot-Marie-Tooth disease, axonal, type 2X, 616668<br>Spastic paraplegia 11, autosomal recessive, 604360<br>Amyotrophic lateral sclerosis 5, juvenile, 602099 |
| SPOCK1  | 118.5 | 100.0% | 98.9%  | No OMIM Disease ID  |
| SPR     | 159.7 | 100.0% | 100.0% | Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716  |
| SPRED1  | 143.0 | 99.8%  | 98.1%  | Legius syndrome, 611431   |
| SPTAN1  | 118.5 | 99.1%  | 98.6%  | Epileptic encephalopathy, early infantile, 5, 613477  |
| SPTBN2  | 141.6 | 100.0% | 99.9%  | Spinocerebellar ataxia, autosomal recessive 14, 615386<br>Spinocerebellar ataxia 5, 600224  |
| SRCAP   | 166.7 | 100.0% | 99.8%  | Floating-Harbor syndrome, 136140  |
| SRD5A3  | 149.2 | 99.9%  | 98.5%  | Kahrizi syndrome, 612713<br>Congenital disorder of glycosylation, type Iq, 612379   |
| SRPX2   | 64.2  | 99.6%  | 94.4%  | ?Rolandic epilepsy, mental retardation, and speech dyspraxia, 300643  |
| SSR4    | 118.5 | 100.0% | 100.0% | Congenital disorder of glycosylation, type Iy, 300934   |
| ST3GAL3 | 143.4 | 100.0% | 99.8%  | Mental retardation, autosomal recessive 12, 611090<br>?Epileptic encephalopathy, early infantile, 15, 615006  |
| ST3GAL5 | 104.4 | 89.3%  | 85.5%  | Salt and pepper developmental regression syndrome, 609056   |

|         |       |        |        |   |
|---------|-------|--------|--------|---|
| STAG1   | 108.3 | 99.8%  | 96.9%  | Mental retardation, autosomal dominant 47, 617635   |
| STAG2   | 72.0  | 96.8%  | 86.9%  | Mullegama-Klein-Martinez syndrome, 301022   |
| STAMBP  | 96.0  | 99.9%  | 97.6%  | Microcephaly-capillary malformation syndrome, 614261  |
| STIL    | 153.2 | 100.0% | 99.7%  | Microcephaly 7, primary, autosomal recessive, 612703  |
| STRA6   | 125.5 | 100.0% | 99.9%  | Microphthalmia, syndromic 9, 601186<br>Microphthalmia, isolated, with coloboma 8, 601186                                |
| STRADA  | 112.5 | 100.0% | 99.5%  | Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087  |
| STT3A   | 125.4 | 100.0% | 99.9%  | ?Congenital disorder of glycosylation, type Iw, 615596  |
| STT3B   | 127.0 | 100.0% | 99.8%  | ?Congenital disorder of glycosylation, type Ix, 615597  |
| STX1B   | 173.7 | 100.0% | 100.0% | Generalized epilepsy with febrile seizures plus, type 9, 616172   |
| STXBP1  | 108.2 | 96.8%  | 96.5%  | Epileptic encephalopathy, early infantile, 4, 612164  |
| SUCLA2  | 57.8  | 91.5%  | 82.6%  | Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073              |
| SUCLG1  | 104.2 | 100.0% | 99.7%  | Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400                    |
| SUMF1   | 91.7  | 99.9%  | 97.6%  | Multiple sulfatase deficiency, 272200   |
| SUOX    | 180.8 | 100.0% | 100.0% | Sulfite oxidase deficiency, 272300  |
| SURF1   | 89.9  | 93.5%  | 89.1%  | Leigh syndrome, due to COX IV deficiency, 256000<br>Charcot-Marie-Tooth disease, type 4K, 616684                        |
| SUZ12   | 102.4 | 95.1%  | 87.5%  | No OMIM Disease ID  |
| SVBP    | 114.3 | 100.0% | 100.0% | Neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, 618569  |
| SYN1    | 73.1  | 93.6%  | 84.0%  | Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491                                  |
| SYNCRIP | 64.1  | 95.0%  | 83.4%  | No OMIM Disease ID  |
| SYNGAP1 | 152.9 | 98.5%  | 98.0%  | Mental retardation, autosomal dominant 5, 612621  |
| SYNJ1   | 126.3 | 99.9%  | 98.5%  | Epileptic encephalopathy, early infantile, 53, 617389<br>Parkinson disease 20, early-onset, 615530                      |
| SYP     | 87.1  | 99.9%  | 98.6%  | Mental retardation, X-linked 96, 300802   |
| SYT1    | 153.0 | 100.0% | 99.1%  | Baker-Gordon syndrome, 618218   |
| SZT2    | 146.3 | 99.6%  | 99.5%  | Epileptic encephalopathy, early infantile, 18, 615476   |
| TAF1    | 89.0  | 99.4%  | 96.2%  | Dystonia-Parkinsonism, X-linked, 314250<br>Mental retardation, X-linked, syndromic 33, 300966                           |
| TAF13   | 96.3  | 100.0% | 100.0% | Mental retardation, autosomal recessive 60, 617432  |
| TAF2    | 110.2 | 99.8%  | 98.1%  | Mental retardation, autosomal recessive 40, 615599  |
| TAF6    | 138.7 | 100.0% | 99.5%  | Alazami-Yuan syndrome, 617126   |
| TANC2   | 140.3 | 99.9%  | 99.3%  | No OMIM Disease ID  |
| TANGO2  | 139.6 | 100.0% | 100.0% | Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, 616878 |
| TAOK1   | 132.6 | 99.0%  | 97.3%  | No OMIM Disease ID  |
| TAT     | 119.7 | 100.0% | 99.9%  | Tyrosinemia, type II, 276600  |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| TBC1D20 | 121.0 | 97.4%  | 94.5%  | Warburg micro syndrome 4, 615663   |
| TBC1D23 | 89.8  | 98.8%  | 94.7%  | Pontocerebellar hypoplasia, type 11, 617695  |
| TBC1D24 | 199.9 | 100.0% | 100.0% | Epilepsy, rolandic, with proxysmal exercise-induce dystonia and writer's cramp, 608105<br>DOORS syndrome, 220500<br>Deafness, autosomal dominant 65, 616044<br>Epileptic encephalopathy, early infantile, 16, 615338<br>Myoclonic epilepsy, infantile, familial, 605021<br>Deafness , autosomal recessive 86, 614617 |
| TBC1D7  | 99.0  | 99.9%  | 99.0%  | Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000  |
| TBCD    | 145.8 | 98.8%  | 95.5%  | Encephalopathy, progressive, early-onset, with brain atrophy and thin corpus callosum, 617193  |
| TBCE    | 117.0 | 99.3%  | 95.6%  | Kenny-Caffey syndrome, type 1, 244460<br>Hypoparathyroidism-retardation-dysmorphism syndrome, 241410<br>Encephalopathy, progressive, with amyotrophy and optic atrophy, 617207   |
| TBCK    | 97.5  | 99.2%  | 94.9%  | Hypotonia, infantile, with psychomotor retardation and characteristic facies 3, 616900   |
| TBL1XR1 | 61.2  | 93.8%  | 78.4%  | Pierpont syndrome, 602342<br>Mental retardation, autosomal dominant 41, 616944   |
| TBP     | 103.4 | 100.0% | 99.8%  | Spinocerebellar ataxia 17, 607136  |
| TBR1    | 184.5 | 100.0% | 100.0% | Intellectual developmental disorder with autism and speech delay, 606053   |
| TBX1    | 114.2 | 93.7%  | 88.3%  | Velocardiofacial syndrome, 192430<br>DiGeorge syndrome, 188400<br>Tetralogy of Fallot, 187500<br>Conotruncal anomaly face syndrome, 217095   |
| TCF20   | 134.1 | 100.0% | 100.0% | Developmental delay with variable intellectual impairment and behavioral abnormalities, 618430   |
| TCF4    | 111.6 | 100.0% | 99.8%  | Corneal dystrophy, Fuchs endothelial, 3, 613267<br>Pitt-Hopkins syndrome, 610954   |
| TCF7L2  | 167.6 | 99.8%  | 98.4%  | No OMIM disease ID   |
| TCN2    | 157.6 | 100.0% | 100.0% | Transcobalamin II deficiency, 275350   |
| TCTN2   | 127.0 | 100.0% | 99.0%  | Joubert syndrome 24, 616654<br>?Meckel syndrome 8, 613885  |
| TCTN3   | 121.0 | 100.0% | 100.0% | Orofaciodigital syndrome IV, 258860<br>Joubert syndrome 18, 614815   |
| TDP2    | 175.8 | 100.0% | 99.9%  | Spinocerebellar ataxia, autosomal recessive 23, 616949   |
| TECPR2  | 147.6 | 100.0% | 100.0% | Spastic paraplegia 49, autosomal recessive, 615031   |
| TECR    | 139.6 | 100.0% | 99.9%  | Mental retardation, autosomal recessive 14, 614020   |
| TELO2   | 136.2 | 99.9%  | 98.7%  | You-Hoover-Fong syndrome, 616954   |
| TFAP2A  | 124.1 | 100.0% | 99.3%  | Branchiooculofacial syndrome, 113620   |
| TGDS    | 84.3  | 99.3%  | 95.0%  | Catel-Manzke syndrome, 616145  |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| TGFBR1  | 156.6 | 97.3%  | 94.3%  | Loeys-Dietz syndrome 1, 609192   |
| TGIF1   | 150.3 | 100.0% | 100.0% | Holoprosencephaly 4, 142946  |
| TH      | 106.8 | 100.0% | 99.2%  | Segawa syndrome, recessive, 605407   |
| THOC2   | 80.5  | 98.6%  | 92.0%  | Mental retardation, X-linked 12/35, 300957   |
| THOC6   | 253.7 | 100.0% | 100.0% | Beaulieu-Boycott-Innes syndrome, 613680  |
| THRB    | 146.5 | 100.0% | 99.3%  | Thyroid hormone resistance, 188570<br>Thyroid hormone resistance, selective pituitary, 145650<br>Thyroid hormone resistance, autosomal recessive, 274300 |
| TIMM50  | 133.8 | 100.0% | 99.4%  | 3-methylglutaconic aciduria, type IX, 617698   |
| TIMM8A  | 50.3  | 95.4%  | 80.0%  | Mohr-Tranebjaerg syndrome, 304700  |
| TINF2   | 190.9 | 100.0% | 100.0% | Revesz syndrome, 268130<br>Dyskeratosis congenita, autosomal dominant 3, 613990  |
| TKT     | 124.8 | 98.7%  | 98.3%  | Short stature, developmental delay, and congenital heart defects, 617044   |
| TLK2    | 89.8  | 98.5%  | 92.8%  | Mental retardation, autosomal dominant 57, 618050  |
| TMCO1   | 82.6  | 87.9%  | 87.3%  | Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980  |
| TMEM165 | 159.2 | 99.9%  | 99.7%  | Congenital disorder of glycosylation, type IIk, 614727   |
| TMEM216 | 92.0  | 99.9%  | 96.9%  | Meckel syndrome 2, 603194<br>Joubert syndrome 2, 608091  |
| TMEM231 | 112.1 | 100.0% | 99.7%  | Meckel syndrome 11, 615397<br>Joubert syndrome 20, 614970  |
| TMEM237 | 114.5 | 99.9%  | 98.8%  | Joubert syndrome 14, 614424  |
| TMEM240 | 184.6 | 100.0% | 100.0% | Spinocerebellar ataxia 21, 607454  |
| TMEM5   | 167.7 | 99.8%  | 96.8%  | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041  |
| TMEM67  | 80.6  | 99.3%  | 93.5%  | Meckel syndrome 3, 607361<br>?RHYS syndrome, 602152<br>Nephronophthisis 11, 613550<br>COACH syndrome, 216360<br>Joubert syndrome 6, 610688               |
| TMEM70  | 117.3 | 99.9%  | 98.5%  | Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052  |
| TMLHE   | 87.6  | 99.9%  | 96.4%  | No OMIM disease ID   |
| TMTC3   | 90.1  | 99.9%  | 97.3%  | Lissencephaly 8, 617255  |
| TNIK    | 107.7 | 99.9%  | 98.9%  | Mental retardation, autosomal recessive 54, 617028   |
| TOE1    | 153.2 | 100.0% | 100.0% | Pontocerebellar hypoplasia, type 7, 614969   |
| TP53RK  | 93.0  | 99.8%  | 97.7%  | Galloway-Mowat syndrome 4, 617730  |
| TPI1    | 120.2 | 99.8%  | 97.4%  | Hemolytic anemia due to triosephosphate isomerase deficiency, 615512   |
| TPO     | 146.9 | 100.0% | 99.9%  | Thyroid dyshormonogenesis 2A, 274500   |



|          |       |        |        |   |
|----------|-------|--------|--------|---|
| TPP1     | 130.2 | 100.0% | 100.0% | Spinocerebellar ataxia, autosomal recessive 7, 609270<br>Ceroid lipofuscinosis, neuronal, 2, 204500   |
| TPRKB    | 57.9  | 81.5%  | 74.8%  | Galloway-Mowat syndrome 5, 617731   |
| TRAF7    | 178.6 | 99.9%  | 98.7%  | Cardiac, facial, and digital anomalies with developmental delay, 618164   |
| TRAIP    | 128.8 | 100.0% | 100.0% | Seckel syndrome 9, 616777   |
| TRAPPC11 | 124.3 | 99.9%  | 99.0%  | Muscular dystrophy, limb-girdle, autosomal recessive 18, 615356   |
| TRAPPC6B | 72.6  | 100.0% | 97.2%  | Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, 617862  |
| TRAPPC9  | 133.0 | 100.0% | 99.8%  | Mental retardation, autosomal recessive 13, 613192  |
| TREX1    | 261.9 | 100.0% | 100.0% | Vasculopathy, retinal, with cerebral leukodystrophy, 192315<br>Aicardi-Goutieres syndrome 1, dominant and recessive, 225750<br>Chilblain lupus, 610448            |
| TRIM32   | 132.8 | 100.0% | 100.0% | ?Bardet-Biedl syndrome 11, 615988<br>Muscular dystrophy, limb-girdle, autosomal recessive 8, 254110   |
| TRIM8    | 179.9 | 100.0% | 99.9%  | No OMIM Disease ID  |
| TRIO     | 129.9 | 99.3%  | 97.5%  | Mental retardation, autosomal dominant 44, 617061   |
| TRIP12   | 132.7 | 100.0% | 99.3%  | Mental retardation, autosomal dominant 49, 617752   |
| TRIT1    | 107.1 | 100.0% | 99.9%  | Combined oxidative phosphorylation deficiency 35, 617873  |
| TRMT1    | 130.7 | 99.9%  | 98.4%  | Mental retardation, autosomal recessive 68, 618302  |
| TRMT10A  | 116.1 | 100.0% | 99.9%  | Microcephaly, short stature, and impaired glucose metabolism 1, 616033  |
| TRNT1    | 100.7 | 99.2%  | 95.3%  | Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084<br>Retinitis pigmentosa and erythrocytic microcytosis, 616959 |
| TRPM3    | 125.7 | 99.8%  | 98.6%  | No OMIM Disease ID  |
| TRRAP    | 145.6 | 99.7%  | 99.2%  | Developmental delay with or without dysmorphic facies and autism, 618454  |
| TSC1     | 117.4 | 99.6%  | 98.4%  | Tuberous sclerosis-1, 191100<br>Focal cortical dysplasia, type II, somatic, 607341<br>Lymphangioliomyomatosis, 606690   |
| TSC2     | 155.5 | 100.0% | 100.0% | Tuberous sclerosis-2, 613254<br>?Focal cortical dysplasia, type II, somatic, 607341<br>Lymphangioliomyomatosis, somatic, 606690                                   |
| TSEN15   | 93.1  | 99.9%  | 96.9%  | Pontocerebellar hypoplasia, type 2F, 617026   |
| TSEN2    | 100.3 | 100.0% | 99.1%  | Pontocerebellar hypoplasia type 2B, 612389  |
| TSEN54   | 129.0 | 99.7%  | 97.9%  | Pontocerebellar hypoplasia type 4, 225753<br>Pontocerebellar hypoplasia type 2A, 277470<br>?Pontocerebellar hypoplasia type 5, 610204                             |
| TSFM     | 123.3 | 100.0% | 99.6%  | Combined oxidative phosphorylation deficiency 3, 610505   |
| TSHB     | 222.2 | 100.0% | 100.0% | Hypothyroidism, congenital, nongoitrous 4, 275100   |
| TSPAN7   | 111.9 | 100.0% | 99.6%  | Mental retardation, X-linked 58, 300210   |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| TTC19   | 84.9  | 98.8%  | 86.6%  | Mitochondrial complex III deficiency, nuclear type 2, 615157   |
| TTC37   | 131.5 | 99.9%  | 98.9%  | Trichohepatoenteric syndrome 1, 222470   |
| TTC8    | 116.8 | 99.7%  | 97.8%  | Bardet-Biedl syndrome 8, 615985<br>?Retinitis pigmentosa 51, 613464  |
| TTI2    | 100.1 | 100.0% | 99.9%  | Mental retardation, autosomal recessive 39, 615541   |
| TUBA1A  | 82.5  | 99.9%  | 97.8%  | Lissencephaly 3, 611603  |
| TUBA8   | 136.6 | 100.0% | 99.5%  | Cortical dysplasia, complex, with other brain malformations 8, 613180  |
| TUBB    | 123.3 | 98.0%  | 94.4%  | Symmetric circumferential skin creases, congenital, 1, 156610<br>Cortical dysplasia, complex, with other brain malformations 6, 615771   |
| TUBB2A  | 83.6  | 99.8%  | 98.0%  | Cortical dysplasia, complex, with other brain malformations 5, 615763  |
| TUBB2B  | 88.3  | 100.0% | 99.9%  | Cortical dysplasia, complex, with other brain malformations 7, 610031  |
| TUBB3   | 135.6 | 99.9%  | 99.1%  | Fibrosis of extraocular muscles, congenital, 3A, 600638<br>Cortical dysplasia, complex, with other brain malformations 1, 614039   |
| TUBB4A  | 114.3 | 97.8%  | 95.9%  | Leukodystrophy, hypomyelinating, 6, 612438<br>Dystonia 4, torsion, autosomal dominant, 128101  |
| TUBG1   | 162.6 | 100.0% | 100.0% | Cortical dysplasia, complex, with other brain malformations 4, 615412  |
| TUBGCP4 | 108.4 | 97.8%  | 95.1%  | Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335   |
| TUBGCP6 | 169.9 | 100.0% | 99.7%  | Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270   |
| TUSC3   | 155.7 | 99.9%  | 99.5%  | Mental retardation, autosomal recessive 7, 611093  |
| TWIST1  | 185.6 | 100.0% | 100.0% | Robinow-Sorauf syndrome, 180750<br>Craniosynostosis 1, 123100<br>Sweeney-Cox syndrome, 617746<br>Saethre-Chotzen syndrome with or without eyelid anomalies, 101400   |
| TWINK   | 170.3 | 100.0% | 100.0% | Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245<br>Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286<br>Perrault syndrome 5, 616138 |
| UBA5    | 79.3  | 96.9%  | 83.9%  | ?Spinocerebellar ataxia, autosomal recessive 24, 617133<br>Epileptic encephalopathy, early infantile, 44, 617132   |
| UBE2A   | 122.1 | 99.6%  | 97.4%  | Mental retardation, X-linked syndromic, Nascimento-type, 300860  |
| UBE3A   | 80.9  | 98.8%  | 92.5%  | Angelman syndrome, 105830  |
| UBE3B   | 119.7 | 100.0% | 99.8%  | Kaufman oculocerebrofacial syndrome, 244450  |
| UBR1    | 118.2 | 99.9%  | 98.9%  | Johanson-Blizzard syndrome, 243800   |
| UBTF    | 127.3 | 100.0% | 99.8%  | Neurodegeneration, childhood-onset, with brain atrophy, 617672   |
| UFC1    | 125.9 | 100.0% | 100.0% | Neurodevelopmental disorder with spasticity and poor growth, 618076  |
| UFM1    | 109.2 | 72.0%  | 69.8%  | Leukodystrophy, hypomyelinating, 14, 617899  |
| UNC13A  | 131.4 | 99.5%  | 97.7%  | No OMIM Disease ID   |
| UNC80   | 114.4 | 100.0% | 99.6%  | Hypotonia, infantile, with psychomotor retardation and characteristic facies 2, 616801   |

|        |       |        |        |  |
|--------|-------|--------|--------|--|
| UPB1   | 150.9 | 100.0% | 100.0% | Beta-ureidopropionase deficiency, 613161   |
| UPF3B  | 60.7  | 94.1%  | 84.6%  | Mental retardation, X-linked, syndromic 14, 300676   |
| UROC1  | 143.4 | 100.0% | 99.9%  | ?Urocanase deficiency, 276880  |
| USP27X | 167.4 | 100.0% | 100.0% | Mental retardation, X-linked 105, 300984   |
| USP7   | 84.8  | 95.1%  | 89.6%  | No OMIM Disease ID   |
| USP9X  | 92.5  | 97.9%  | 91.6%  | Mental retardation, X-linked 99, 300919<br>Mental retardation, X-linked 99, syndromic, female-restricted, 300968                           |
| VAMP1  | 142.3 | 100.0% | 100.0% | Spastic ataxia 1, autosomal dominant, 108600<br>Myasthenic syndrome, congenital, 25, 618323  |
| VAMP2  | 104.1 | 99.9%  | 99.2%  | No OMIM Disease ID   |
| VAR5   | 142.4 | 100.0% | 99.9%  | Neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, 617802  |
| VDLDR  | 145.5 | 100.0% | 100.0% | Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050  |
| VPS11  | 125.6 | 95.5%  | 93.8%  | Leukodystrophy, hypomyelinating, 12, 616683  |
| VPS13B | 135.9 | 99.4%  | 97.8%  | Cohen syndrome, 216550   |
| VPS37A | 61.7  | 89.1%  | 74.8%  | Spastic paraplegia 53, autosomal recessive, 614898   |
| VPS53  | 117.2 | 91.3%  | 89.9%  | Pontocerebellar hypoplasia, type 2E, 615851  |
| VRK1   | 126.7 | 99.9%  | 98.3%  | Pontocerebellar hypoplasia type 1A, 607596   |
| VWA3B  | 130.0 | 100.0% | 99.3%  | ?Spinocerebellar ataxia, autosomal recessive 22, 616948  |
| WAC    | 142.4 | 100.0% | 99.2%  | Desanto-Shinawi syndrome, 616708   |
| WARS2  | 142.1 | 99.9%  | 99.1%  | Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, 617710                  |
| WASF1  | 85.7  | 100.0% | 98.7%  | No OMIM Disease ID   |
| WASHC4 | 104.0 | 98.9%  | 94.9%  | ?Mental retardation, autosomal recessive 43, 615817  |
| WDFY3  | 125.5 | 100.0% | 99.3%  | ?Microcephaly 18, primary, autosomal dominant, 617520  |
| WDPCP  | 105.7 | 97.1%  | 93.6%  | ?Bardet-Biedl syndrome 15, 615992<br>?Congenital heart defects, hamartomas of tongue, and polysyndactyly, 217085                           |
| WDR13  | 125.7 | 100.0% | 99.8%  | No OMIM Disease ID   |
| WDR26  | 97.7  | 99.9%  | 98.4%  | Skraban-Deardorff syndrome, 617616   |
| WDR37  | 152.1 | 100.0% | 98.9%  | Neurooculocardiogenitourinary syndrome, 618652   |
| WDR4   | 152.7 | 100.0% | 100.0% | Microcephaly, growth deficiency, seizures, and brain malformations, 618346<br>Galloway-Mowat syndrome 6, 618347                            |
| WDR45  | 74.7  | 97.1%  | 90.6%  | Neurodegeneration with brain iron accumulation 5, 300894   |
| WDR45B | 75.6  | 97.4%  | 90.3%  | Neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, 617977                             |
| WDR62  | 166.4 | 100.0% | 100.0% | Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317   |
| WDR73  | 164.4 | 100.0% | 100.0% | Galloway-Mowat syndrome 1, 251300  |
| WDR81  | 205.5 | 100.0% | 100.0% | Hydrocephalus, congenital, 3, with brain anomalies, 617967<br>Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 |

|         |       |        |        |  |
|---------|-------|--------|--------|--|
| WFS1    | 210.0 | 100.0% | 99.8%  | ?Cataract 41, 116400<br>Deafness, autosomal dominant 6/14/38, 600965<br>Wolfram-like syndrome, autosomal dominant, 614296<br>Wolfram syndrome 1, 222300                |
| WVOX    | 122.0 | 100.0% | 100.0% | Esophageal squamous cell carcinoma, somatic, 133239<br>Spinocerebellar ataxia, autosomal recessive 12, 614322<br>Epileptic encephalopathy, early infantile, 28, 616211 |
| XPA     | 73.5  | 99.9%  | 97.6%  | Xeroderma pigmentosum, group A, 278700   |
| XRCC4   | 139.7 | 100.0% | 99.2%  | Short stature, microcephaly, and endocrine dysfunction, 616541   |
| XYLT1   | 138.1 | 100.0% | 99.4%  | Desbuquois dysplasia 2, 615777   |
| YME1L1  | 102.3 | 98.1%  | 92.4%  | ?Optic atrophy 11, 617302  |
| YWHAE   | 117.3 | 100.0% | 100.0% | No OMIM Disease ID   |
| YWHAG   | 181.4 | 100.0% | 100.0% | Epileptic encephalopathy, early infantile, 56, 617665  |
| YY1     | 146.4 | 100.0% | 99.1%  | Gabriele-de Vries syndrome, 617557   |
| ZBTB11  | 165.5 | 100.0% | 99.6%  | Intellectual developmental disorder, autosomal recessive 69, 618383  |
| ZBTB16  | 161.1 | 100.0% | 100.0% | Skeletal defects, genital hypoplasia, and mental retardation, 612447<br>Leukemia, acute promyelocytic, PL2F/RARA type, 0   |
| ZBTB18  | 185.2 | 99.9%  | 99.4%  | Mental retardation, autosomal dominant 22, 612337  |
| ZBTB20  | 199.5 | 100.0% | 100.0% | Primrose syndrome, 259050  |
| ZBTB24  | 160.7 | 100.0% | 100.0% | Immunodeficiency-centromeric instability-facial anomalies syndrome 2, 614069   |
| ZC3H14  | 153.9 | 99.9%  | 98.4%  | Mental retardation, autosomal recessive 56, 617125   |
| ZC4H2   | 74.3  | 99.6%  | 95.6%  | Wieacker-Wolff syndrome, 314580  |
| ZDHHC9  | 50.3  | 98.4%  | 89.1%  | Mental retardation, X-linked syndromic, Raymond type, 300799   |
| ZEB2    | 145.0 | 99.7%  | 98.6%  | Mowat-Wilson syndrome, 235730  |
| ZFYVE26 | 110.8 | 99.9%  | 99.0%  | Spastic paraplegia 15, autosomal recessive, 270700   |
| ZIC1    | 319.7 | 100.0% | 100.0% | Craniosynostosis 6, 616602   |
| ZIC2    | 190.6 | 98.4%  | 96.3%  | Holoprosencephaly 5, 609637  |
| ZMIZ1   | 155.5 | 99.9%  | 99.3%  | Neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, 618659   |
| ZMYND11 | 119.7 | 100.0% | 99.6%  | Mental retardation, autosomal dominant 30, 616083  |
| ZNF148  | 157.2 | 100.0% | 99.9%  | Global developmental delay, absent or hypoplastic corpus callosum, and dysmorphic facies, 617260   |
| ZNF292  | 133.2 | 99.5%  | 98.5%  | No OMIM Disease ID   |
| ZNF335  | 147.5 | 100.0% | 99.9%  | Microcephaly 10, primary, autosomal recessive, 615095  |
| ZNF407  | 161.7 | 99.9%  | 99.3%  | No OMIM Disease ID   |
| ZNF41   | 89.3  | 100.0% | 99.6%  | No OMIM Disease ID   |
| ZNF462  | 164.9 | 100.0% | 99.8%  | Weiss-Kruszka syndrome, 618619   |
| ZNF711  | 110.7 | 99.7%  | 97.4%  | Mental retardation, X-linked 97, 300803  |

|        |       |       |       |   |
|--------|-------|-------|-------|---|
| ZSWIM6 | 127.2 | 97.5% | 95.6% | Acromelic frontonasal dysostosis, 603671<br>Neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, 617865 |
|--------|-------|-------|-------|---|

*Gene symbols used follow HGNC guidelines: Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Nucleic Acids Res. 2015 Jan 43(Database issue):D1079-85.*

*Median Coverage describes the average number of reads seen across 50 exomes.*

*% Covered 10x describes the percentage of a gene's coding sequence that is covered at least 10x.*

*% Covered 20x describes the percentage of a gene's coding sequence that is covered at least 20x.*

*Genes with Median Coverage and % Covered 10x/20x denoting NC are non-coding genes for which coverage statistics could not be generated.*

*OMIM release used for OMIM disease identifiers and descriptions : December 11<sup>th</sup>, 2019.*

*This list is accurate for panel version DG 2.17*

*Ad 1. "No OMIM phenotype" signifies a gene without a current OMIM association Ad 2. OMIM phenotype descriptions between {} signify risk factors*

---